Healthcare Triangle Q3 2026 loss widens to $2.53M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Healthcare Triangle, Inc. (HCTI) reported third-quarter 2026 revenue of $9.116 million, versus $3.489 million a year earlier; customer engagement services contributed $6.525 million following the January 1, 2026 acquisition of Teyame and Datono. Gross margin was $2.081 million, while net loss was $2.532 million, compared with $1.906 million a year earlier.
For the nine months ended September 30, revenue was $28.162 million and net loss was $13.147 million. Operating cash outflow was $10.207 million, and cash and equivalents were $1.869 million on September 30, down from $7.625 million on December 31, 2025. Management said resources were sufficient to meet obligations for at least 12 months from issuance, citing net assets of $50.238 million, an equity line allowing common-stock sales up to $50 million subject to contractual conditions, and access to an at-the-market sales agreement. A one-for-twenty reverse stock split took effect October 26, 2026. An appeal stayed Nasdaq trading suspension and delisting proceedings pending a panel decision; HCTI presented its case on November 5, 2026, and is awaiting the decision.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter revenue increased 161% year over year to $9.116 million.
Negative
- Moderate pointThird-quarter net loss increased to $2.532 million from $1.906 million.
- Moderate pointCash and equivalents fell to $1.869 million at September 30 from $7.625 million at year-end.
Filing Explained
The proposed Teyame separation would distribute only a portion of its shares to Healthcare Triangle holders, with the company retaining control.
Healthcare Triangle reported a
By quarter-end, the company had completed two Hudson line draws, leaving approximately
After quarter-end, the company said it was advancing a proposed separation and direct listing of Teyame AI Holdings: it intends to distribute a portion of Teyame’s shares to Healthcare Triangle stockholders while retaining control. The transaction is not complete and remains subject to registration, regulatory and exchange requirements, approvals and other conditions.
Also after quarter-end, the company issued 28,602 common shares through its ATM. Issuing additional shares reduces existing holders’ percentage ownership absent offsetting changes.
Key Figures
Key Terms
At-the-Market Sales Agreement financial
Equity Purchase Agreement financial
original issue discount financial
volume-weighted average price financial
Level 3 financial
cost-to-cost method financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did HCTI report in Q3 2026?
How much capacity remained under HCTI’s equity line at September 30, 2026?
What are the amended purchase terms for HCTI’s Hudson equity line?
What is HCTI’s Nasdaq listing status?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For the quarterly period ended
For the transition period from __________ to __________
Commission file number
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
|
| (Address of principal executive offices) | (Zip Code) | |
| (Registrant’s telephone number, including area code) | ||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | Smaller reporting company | Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes ☐ No
As of November 11, 2026,
Table of Contents
| Note About Forward-Looking Statements | ii | |
| PART I – FINANCIAL INFORMATION | 1 | |
| Item 1. Financial Statements | 1 | |
| Unaudited Condensed Consolidated Balance Sheets | 1 | |
| Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss | 2 | |
| Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) | 3 | |
| Unaudited Condensed Consolidated Statements of Cash Flows | 6 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 7 | |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 31 | |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 47 | |
| Item 4. Controls and Procedures | 47 | |
| PART II - OTHER INFORMATION | 48 | |
| Item 1. Legal Proceedings | 48 | |
| Item 1A. Risk Factors | 48 | |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 48 | |
| Item 3. Defaults Upon Senior Securities | 48 | |
| Item 4. Mine Safety Disclosures | 48 | |
| Item 5. Other Information | 48 | |
| Item 6. Exhibits | 49 | |
| Signatures | 50 |
i
NOTE ABOUT FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, involving substantial risks and uncertainties. The words “believe,” “may,” “will,” “potentially,” “plan,” “could,” “should,” “predict,” “ongoing,” “estimate,” “continue,” “anticipate,” “intend,” “project,” “expect,” “seek,” or the negative of these words, or terms or similar expressions conveying uncertainty of future events or outcomes, or that concern our expectations, strategy, plans or intentions, are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or expected. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026, as amended, and in our other publicly available filings and press releases. These statements include, among other things, those regarding:
| ● | our ability to continue to add new customers and increase sales to our existing customers; |
| ● | our ability to develop new solutions and bring them to market in a timely manner; |
| ● | our ability to timely and effectively scale and adapt our existing solutions; |
| ● | our dependence on establishing and maintaining a strong brand; |
| ● | the occurrence of service interruptions and security or privacy breaches and related remediation efforts and fines; |
| ● | system failures or capacity constraints; |
| ● | the rate of growth of, and anticipated trends and challenges in, our business and in the market for our products; |
| ● | our future financial performance, including our expectations regarding our revenue, cost of revenue, operating expenses, including changes in technology and development, marketing and advertising, general and administrative and customer care expenses, and our ability to achieve and maintain future profitability; |
| ● | our ability to continue to efficiently acquire customers, maintain our high customer retention rates and maintain the level of our customers’ lifetime spend; |
| ● | our ability to provide high-quality customer care; |
| ● | the effects of increased competition in our markets and our ability to compete effectively; |
| ● | our ability to grow internationally; |
| ● | the impact of fluctuations in foreign currency exchange rates on our business and our ability to effectively manage the exposure to such fluctuations; |
| ● | our ability to effectively manage our growth and associated investments, including our migration of the vast majority of our infrastructure to the public cloud; |
| ● | our ability to maintain our relationships with our partners; |
| ● | adverse consequences of our substantial level of indebtedness and our ability to repay our debt; |
| ● | our ability to maintain, protect and enhance our intellectual property; |
ii
| ● | our ability to maintain or improve our market share; |
| ● | our ability to continue generating cashflows and to maintain sufficiency of cash and cash equivalents to meet our needs for at least the next 12 months; |
| ● | beliefs and objectives for future operations; |
| ● | our ability to stay in compliance with laws and regulations currently applicable to, or which may become applicable to, our business both in the United States (U.S.) and internationally; |
| ● | economic and industry trends or trend analysis; |
| ● | our ability to attract and retain qualified employees and key personnel; |
| ● | anticipated income tax rates, tax estimates and tax standards; |
| ● | interest and other embedded rate changes; |
| ● | the future trading prices of our common stock; |
| ● | our expectations regarding the outcome of any regulatory investigation or litigation; |
| ● | the amount and timing of future repurchases of our common stock under any share repurchase program; |
| ● | the potential impact of shareholder activism on our business and operations; and |
| ● | the length and severity of pandemics and their impact on our business, customers and employees; as well as other statements regarding our future operations, financial condition, growth prospects and business strategies. |
We operate in very competitive and rapidly changing environments, and new risks emerge from time-to-time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this report may not occur, and actual results could differ materially and adversely from those implied in our forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to publicly update any forward-looking statements for any reason after the date of this report to conform such statements to actual results or to changes in our expectations, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.
Unless expressly indicated or the context suggests otherwise, references to “Healthcare Triangle,” “company,” “we,” “us” and “our” refer to Healthcare Triangle, Inc. and its consolidated subsidiaries.
iii
PART I
FINANCIAL INFORMATION
Item 1. Financial statements (In thousands of US $, unless otherwise noted)
HEALTHCARE TRIANGLE, INC.
Unaudited Condensed Consolidated Balance Sheets
| September 30, | December 31, | |||||||||||
| Note | 2026 | 2025 | ||||||||||
| (Unaudited) | (Audited) | |||||||||||
| Assets | ||||||||||||
| Current assets | ||||||||||||
| Cash and cash equivalents | $ | $ | ||||||||||
| Accounts receivable, net | 3 | |||||||||||
| Other current assets | 4 | |||||||||||
| Total current assets | ||||||||||||
| Advances, net | 5 | |||||||||||
| Furniture and equipment, net | 7 | |||||||||||
| Other intangible assets, net | 6 | |||||||||||
| Goodwill | 6 | |||||||||||
| Operating lease right-of-use assets | 8 | - | ||||||||||
| Other non-current assets | 9 | - | ||||||||||
| Total assets | $ | $ | ||||||||||
| Liabilities and stockholders’ equity | ||||||||||||
| Current liabilities | ||||||||||||
| Accounts payable | $ | $ | ||||||||||
| Short-term debt | 10 | |||||||||||
| Operating lease liabilities – current | 8 | - | ||||||||||
| Other current liabilities | 11 | |||||||||||
| Total current liabilities | ||||||||||||
| Non-current liabilities | ||||||||||||
| Long-term debt | 10 | - | ||||||||||
| Operating lease liabilities - non-current | 8 | - | ||||||||||
| Contingent consideration | 6,12 | - | ||||||||||
| Other non-current liabilities | - | |||||||||||
| Total liabilities | ||||||||||||
| Stockholders’ equity | 13 | |||||||||||
| Preferred stock, par value $ | ||||||||||||
| Series A super voting preferred stock - | - | - | ||||||||||
| Series B convertible preferred stock, nil and | - | |||||||||||
| Common stock, par value $ | - | |||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||||||
| Total equity attributable to HCTI stockholders | ||||||||||||
| Non-controlling interest | ( | ) | ( | ) | ||||||||
| Total stockholders’ equity | ||||||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
1
HEALTHCARE TRIANGLE, INC.
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||||
| Note | 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Net revenue | $ | $ | $ | $ | ||||||||||||||
| Cost of revenue (exclusive of depreciation and amortization shown separately below) | ||||||||||||||||||
| Gross margin | ||||||||||||||||||
| Operating expenses | ||||||||||||||||||
| Sales and marketing | ||||||||||||||||||
| General and administrative | ||||||||||||||||||
| Research and development | ||||||||||||||||||
| Bad debt expense | ( | ) | ( | ) | ||||||||||||||
| Depreciation and amortization | 6,7 | |||||||||||||||||
| Total operating expenses | ||||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||
| Other income | ||||||||||||||||||
| Changes in fair value | 10 | ( | ) | - | ( | ) | - | |||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||
| Forex loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||
| Loss before income tax | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||
| Income tax reversal / (expense) | - | ( | ) | - | ||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Other comprehensive income (OCI) | ||||||||||||||||||
| Foreign currency translation gain | ||||||||||||||||||
| Comprehensive loss | $ | ( | ) | ( | ) | $ | ( | ) | ( | ) | ||||||||
| Comprehensive loss attributable to: | ||||||||||||||||||
| Stockholders | $ | ( | ) | ( | ) | $ | ( | ) | ( | ) | ||||||||
| Non-controlling interest | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||
| Net (loss) per common share - basic and diluted, attributable to stockholders | 17 | - | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income per common share - basic attributable to stockholders | 17 | - | - | - | ||||||||||||||
| Net income per common share – diluted attributable to stockholders | 17 | - | - | - | ||||||||||||||
| Stockholders- Diluted | ||||||||||||||||||
| Weighted average shares outstanding used in per common share computations: | ||||||||||||||||||
| Basic | ||||||||||||||||||
| Diluted | - | - | - | |||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2
HEALTHCARE TRIANGLE, INC.
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Preferred
stock (Series A) |
Preferred
stock (Series B) |
Preferred
stock (Series C, to be issued) |
Common stock | Additional paid-in | Non-controlling | Accumulated | Total stockholders’ | |||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares(*) | Amount | Shares | Amount | Shares | Amount | capital | interest | deficit | equity | |||||||||||||||||||||||||||||||||||||
| Three months ended September 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Transfer to additional paid-in capital | ( | ) | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
| Effects of exchange translation reserve (OCI) | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Equity line of credit – Hudson shares | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||
| Common stock issued for cash (ELOC)- gross proceeds | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Less: ELOC issuance expenses | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for cash (ATM placements)- gross proceeds received | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Less: Placement commission | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||
| Shares buy back at market(1) | - | - | - | - | - | - | - | - | ( | ) | - | - | ( | ) | ||||||||||||||||||||||||||||||||||
| Extinguishment and exchange of Series B preferred stock to common equity | - | - | ( | ) | ( | ) | - | - | - | - | ( | ) | ||||||||||||||||||||||||||||||||||||
| Issuance of stock in connection with business combination | - | - | - | - | - | ( | ) | - | - | - | - | |||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
| (1) |
3
HEALTHCARE TRIANGLE, INC.
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Preferred
stock (Series A) |
Preferred
stock (Series B) |
Common stock | Additional paid-in | Non-controlling | Accumulated | Total stockholders’ | ||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares(*) | Amount | Shares | Amount | capital | interest | deficit | equity | |||||||||||||||||||||||||||||||
| Nine months ended September 30, 2026 | ||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2025 | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Transfer to additional paid-in capital | ( | ) | - | |||||||||||||||||||||||||||||||||||||
| Effects of exchange translation reserve (OCI) | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||
| Common stock, pre-funded warrants and preferred stock issued for acquisition(1) | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Common stock issued for cash (ATM placements)- gross proceeds received | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Less: Placement commission | - | - | - | - | - | - | ( | ) | - | - | ( | ) | ||||||||||||||||||||||||||||
| Shares buy back at market(3) | - | - | - | - | - | - | ( | ) | - | - | ( | ) | ||||||||||||||||||||||||||||
| Equity line of credit – Hudson shares (2) | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Common stock issued for cash (ELOC) | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Less: ELOC issuance costs | - | - | - | - | - | - | ( | ) | - | - | ( | ) | ||||||||||||||||||||||||||||
| Extinguishment and exchange of Series B preferred stock to common equity | - | - | ( | ) | ( | ) | - | - | ( | ) | ||||||||||||||||||||||||||||||
| Conversion of debt to equity | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Equity issued pursuant to a financing arrangement | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Less: Issuance costs | - | - | - | - | - | ( | ) | - | - | ( | ) | |||||||||||||||||||||||||||||
| Balance at September 30, 2026 | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| (*) | |
| (1) | |
| (2) | |
| (3) | During September 2026, pursuant to its previously announced share repurchase program, the Company executed a single transaction to repurchase 127,248 shares of its common stock (equivalent to approximately 6,362 shares following the one-for-twenty reverse stock split effective October 26, 2026, before fractional-share adjustments). As of September 30, 2026, the transfer of these shares to the Company remained pending. Upon completion of the transfer, the Company intends to cancel and retire the repurchased shares. |
4
HEALTHCARE TRIANGLE, INC.
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Preferred
stock (Series A) |
Preferred
stock (Series B) |
Common stock | Additional paid-in |
Equity to be |
Non-controlling | Accumulated | Total stockholders’ equity |
|||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | capital | issued | Interest | deficit | (deficit) | ||||||||||||||||||||||||||||||||||
| Three months ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | - | $ | $ | $ | - | - | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Effects of exchange translation reserve (OCI) | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Issue of Options (ISO/NSO) | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Cancellation of shares | - | - | - | - | ( | ) | ( | ) | ( | ) | - | - | - | ( | ) | |||||||||||||||||||||||||||||
| Shares to be issued | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | - | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Nine months ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Shares issued for services | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Effects of exchange translation reserve | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Common stock issued for cash | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Prefunded warrants issued for cash | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Series B (cashless warrants) | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||
| Expenses relating to funding | - | - | - | - | - | - | ( | ) | - | - | - | ( | ) | |||||||||||||||||||||||||||||||
| Shares issued for acquisition | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||
| Conversion of Debt to Equity | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Shares issued for acquisition (contingent consideration) | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Cancellation of shares | - | - | - | - | ( | ) | ( | ) | ( | ) | - | - | - | ( | ) | |||||||||||||||||||||||||||||
| Shares to be issued | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | - | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
HEALTHCARE TRIANGLE, INC.
Unaudited Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, |
||||||||||||
| Note | 2026 | 2025 | ||||||||||
| (In ’000) | ||||||||||||
| Cash flows from operating activities | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||||||
| Adjustment to reconcile net loss to net cash provided by / (used in) operating activities | ||||||||||||
| Depreciation and amortization | ||||||||||||
| Net unrealized exchange loss | ||||||||||||
| Change in fair value | - | |||||||||||
| Common stock issued for services | - | |||||||||||
| Amortization of debt discount | - | |||||||||||
| Other income | ( | ) | ( | ) | ||||||||
| Stock compensation expenses | - | |||||||||||
| Interest expenses | ||||||||||||
| Interest expenses settled by equity | - | |||||||||||
| Right-of-use lease expenses | - | |||||||||||
| Bad debt expense | 3 | ( | ) | |||||||||
| Changes in working capital: | ||||||||||||
| Accounts receivable | ( | ) | ||||||||||
| Other current assets | ( | ) | ( | ) | ||||||||
| Due from affiliates | - | ( | ) | |||||||||
| Accounts payable | ( | ) | ( | ) | ||||||||
| Other current liabilities | ( | ) | ||||||||||
| Payment of lease liability | 8 | ( | ) | - | ||||||||
| Interest paid | ( | ) | ( | )* | ||||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||||||
| Cash flows from investing activities | ||||||||||||
| Purchase of furniture and equipment | ( | ) | ( | ) | ||||||||
| Disposal of furniture and equipment | - | |||||||||||
| Acquisition of intangible assets | - | ( | ) | |||||||||
| Acquisition of Teyame, net of cash acquired on business combination | 6 | ( | ) | - | ||||||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||||||
| Cash flows from financing activities | ||||||||||||
| Proceeds from debt | 10 | - | ||||||||||
| Decrease in short term borrowing | 10 | ( | ) | ( | ) | |||||||
| Repayment of debt | 10 | ( | ) | - | ||||||||
| Proceeds from equity issuance | ||||||||||||
| Share buy-back at market | ( | ) | - | |||||||||
| Net cash provided by financing activities | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | ( | ) | - | |||||||||
| Net (decrease)/increase in cash and cash equivalents | ( | ) | ||||||||||
| Cash and cash equivalents | ||||||||||||
| Cash and cash equivalents at the beginning of the year | ||||||||||||
| Cash and cash equivalents at the end of the period | $ | $ | ||||||||||
| Supplementary disclosure of cash flows information | ||||||||||||
| Deferred offering cost | $ | $ | - | |||||||||
| Investment in platform development work-in-progress | - | |||||||||||
| Conversion of debt to common stock | - | |||||||||||
| Acquisition of Teyame | 6 | (B) | - | |||||||||
| Settlement of Series B convertible preferred stock (including advance settlement of $ | 13 | (B) | - | |||||||||
| Equity to be issued | - | |||||||||||
| Operating right-of-use asset | - | |||||||||||
| Acquisition of assets | $ | - | $ | |||||||||
| (*) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
Organization and Description of Business
Healthcare Triangle, Inc. (“HTI” or “the Company”) was incorporated under the laws of the State of Nevada on October 29, 2019, and converted into a Delaware corporation on
During 2025, the Company, through its wholly owned subsidiary QuantumNexis Inc., a Delaware corporation, entered into an Asset and Stock Transfer Agreement (ATA) with Niyama Healthcare Inc., a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”). Pursuant to the ATA, the Company purchased (i) the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii)
Effective January 1, 2026, the Company, through its wholly owned subsidiary Teyame AI Holdings Inc., a Delaware corporation, acquired Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) (see note 6[B] for details). Together, Teyame and Datono operate as an integrated platform providing AI-powered omnichannel customer experience, marketing, financial and insurance distribution services.
Teyame leverages its technology solutions to provide customer engagement services that combine artificial intelligence, telemarketing, and contact center operations to support customer acquisition, retention, and service. Its platform enables enterprises particularly in financial services, insurance, and healthcare to manage end-to-end customer interactions across multiple channels.
Datono complements this platform as an insurance brokerage entity, facilitating the marketing and sales of insurance products. Together, the companies form a vertically integrated model combining customer acquisition technology with distribution capabilities, particularly in regulated sectors such as insurance.
Liquidity Risk
The Company incurred loss from operations of $
| 1) | Basis of Preparation of Unaudited Condensed Consolidated Financial Statements |
These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission, or SEC, Regulation S-X. The December 31, 2025, consolidated balance sheet was derived from our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, but does not include all disclosures required by U.S. GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of items of a normal and recurring nature, necessary to present fairly our financial position as of September 30, 2026, the results of operations, comprehensive loss, and stockholders’ equity (deficit) for the three and nine months ended September 30, 2026, and 2025, and cash flows for the nine months ended September 30, 2026, and 2025. The results of operations for the periods presented are not necessarily indicative of the results to be expected for any future period. The information contained herein should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC. Management considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date of issuance of these condensed consolidated financial statements.
All intercompany balances and transactions have been eliminated upon consolidation.
Certain balances from the prior fiscal year have been reclassified to conform to the current period presentation.
7
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
| 2) | Summary of Significant Accounting Policies |
Revenue Recognition
We recognize revenues as we transfer control of deliverables (services, solutions, and platform) to our clients in an amount reflecting the consideration to which we expect to be entitled. To recognize revenues, we apply the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenues when a performance obligation is satisfied. We account for a contract when it has approval and commitment from all parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We apply judgment in determining the customer’s ability and intention to pay based on factors including historical payment experience, credit profile, and geographic and industry risk factors. For customers acquired through business combinations, collectability is assessed using the acquired entity’s collection history with those customers, supplemented by post-acquisition payment performance. A contract is recognized only where collectability of substantially all consideration is probable.
For performance obligations where control is transferred over time, revenues are recognized based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the deliverables to be provided.
The Company accounts for revenue from a contract after it is approved by the customer, and after ensuring that the rights of each party regarding the services to be transferred, the payment terms, the commercial substance, and the collectability are ascertained. In assessing collectability, the Company applies judgment and considers factors such as the customer’s credit profile, past payment behavior, and the nature and geography of the customer relationship.
Contract modifications, such as changes in scope, rates, or duration, are assessed to determine whether they should be accounted for as a separate contract or as part of the existing contract. A modification is treated as a separate contract when it adds services at a price that reflects their standalone selling price. Otherwise, the modification is combined with the existing contract, and the transaction price is updated on a prospective or cumulative catch-up basis, as appropriate.
When it becomes probable that total costs to satisfy a contract will exceed the transaction price, the expected loss is recognized in full in the period in which the loss becomes probable and can be reasonably estimated, regardless of whether work has commenced under the contract.
8
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
Revenue is earned and recognized in the following segments:
| A. | Software Services |
The Company enters into contractual obligations with the customers to perform (i) Strategic advisory services which include assessment of the enterprise network, applications environment and advise on the design and tools; (ii) Implementation services which include deployment, upgrades, enhancements, migration, training, documentation and maintenance of various electronic health record systems and (iii) Development services which include customization of network and applications in the public cloud environment.
Revenue from Strategic advisory, Implementation and Development services are distinct performance obligation and is recognized on time-and-material or fixed-price project basis. Revenues related to time-and-material are recognized over the period the services are provided using labor hours. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract’s total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized immediately, where appropriate.
We may enter into contracts that consist of multiple performance obligations. Such contracts may include any combination of our deliverables. To the extent a contract includes multiple promised deliverables, we apply judgment to determine whether promised deliverables are capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised deliverables are accounted for as a combined performance obligation. For contracts with multiple distinct performance obligations, we allocate consideration among the performance obligations based on their relative standalone selling price. Standalone selling price is the price at which we would sell a promised good or service separately to the customer. When not directly observable, we estimate standalone selling price by using the expected cost plus a margin approach. We establish a standalone selling price range for our deliverables, which is reassessed on a periodic basis or when facts and circumstances change.
Contract modifications, such as extensions of statement of work duration or changes in resources and rates, are evaluated under ASC 606 and accounted for prospectively as a separate contract or modification of the existing contract, based on whether the modification adds distinct performance obligations at standalone selling prices.
When the estimated costs to complete a performance obligation exceed the expected transaction price, the full amount of the anticipated loss is recognized immediately in the period in which the loss becomes probable and estimable.
Certain contracts include variable consideration such as rate adjustments, which is estimated using the most likely amount method and included in the transaction price only to the extent that a significant revenue reversal is not probable. Estimates are reassessed at each reporting date.
9
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
| B. | Managed Services and Support |
The Company has standard contracts for its Managed Services and Support, however the statement of work contained in such contracts is unique for each customer. A typical Managed Services and Support contract would provide for some or all of the following types of services being provided to the customer: Cloud hosting, Continuous monitoring of applications, security and compliance and support.
Revenue from Managed services and support is a distinct performance obligation and recognized based on Standalone Selling Price (SSP), ratably on a straight-line basis over the period in which the services are rendered. Contract with customers includes subcontractor services or third-party cloud infrastructure services in certain integrated services arrangements. In these types of arrangements, revenue is recognized net of costs when the Company is acting as an agent between the customer and the vendor, and gross when the Company is the principal for the transaction. In doing so, the Company first evaluates whether it controls the platform or service before it is transferred to the customer. The Company considers whether it has the primary obligation to fulfil the contract, pricing discretion and other factors to determine whether it controls the platform or service and therefore is acting as principal or agent.
| C. | Customer Engagement Services |
The Customer Engagement Services segment, acquired through business combination (see note 6), provides customer search, marketing, telemarketing and customer-support services to financial institutions, insurance companies and intermediaries, and other customers. These services include the promotion and distribution of banking, credit and insurance products; outbound and inbound telemarketing; lead generation and customer-search campaigns; appointment setting; customer service and satisfaction surveys; and technology-enabled digital marketing and customer-interaction services supporting customers’ digital search and customer-care strategies.
The Company recognizes revenue from Customer Engagement Services in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when or as the Company satisfies its performance obligations by transferring the promised services to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services.
Under these arrangements, the Company generally performs the customer-engagement services using its own personnel, processes, systems and operational infrastructure and is primarily responsible for fulfilling the promised services in accordance with contractual requirements and applicable quality standards. The Company has determined that it controls the specified services before they are transferred to the customer and, accordingly, acts as the principal in these arrangements and recognizes revenue on a gross basis.
Consideration under Customer Engagement Services arrangements is generally based on either a fee for each completed and validated outcome or an agreed hourly rate for services provided.
For success-based arrangements, revenue is recognized at a point in time when the applicable contractual outcome has been completed and validated by the customer in accordance with contractual terms. To the extent such consideration is variable, revenue is recognized only to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur.
For hourly service arrangements, revenue is recognized over time as the services are performed because the customer simultaneously receives and consumes the benefits of the Company’s performance. Revenue is measured based on the contracted hourly rate and the actual hours of service provided during the applicable reporting period.
Revenue is presented net of estimated cancellations, penalties and other adjustments to the extent such amounts represent adjustments to the transaction price under the applicable customer contracts.
| D. | All others |
This segment includes Platform Services revenue. A typical Platform Services contract would provide for some or all of the following types of services being provided to the customer: Data Analytics, Backup and Recovery, through our Platform with contract terms unique to each customer. The Company delivers Platform Services through its proprietary platform. Where third-party technology or infrastructure is included in the arrangement, the Company evaluates whether it is acting as principal or agent based on whether it controls the service before transfer to the customer.
10
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
The revenue from Platform Services is a distinct performance obligation and recognized based on SSP. During the periods presented the Company generated revenue from Platform Services on a fixed-price solutions delivery model. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract’s total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized in full in the period in which the loss becomes probable and estimable.
Our contractual terms and conditions for revenue mandate that our services are documented and subject to inspection, testing at the time of delivery to customer. In addition, the Company needs to integrate seamlessly into the customers’ systems. Also, the customer has a right to cancel all, or part of the services rendered if it is not in accordance with statement of work and within the stipulated time.
Fair Value Measurements
| September 30, 2026 | ||||||||||||||||
| Fair Value Measured Using | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Financial Assets: | ||||||||||||||||
| Cash and cash equivalents | $ | — | — | $ | ||||||||||||
| Financial liabilities: | ||||||||||||||||
| 2026 Convertible Notes (refer note 10[C]) | — | — | $ | $ | ||||||||||||
| Contingent consideration | — | — | $ | $ | ||||||||||||
| December 31, 2025 | ||||||||||||||||
| Fair Value Measured Using | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Financial Assets: | ||||||||||||||||
| Cash and cash equivalents | $ | — | — | $ | ||||||||||||
| Financial liabilities: | ||||||||||||||||
| 2025 Convertible Notes (refer note 10[B]) | $ | — | — | * | $ | |||||||||||
| (*) |
Concentration
The Company monitors the credit worthiness of its customers through various factors, including review of their financial statements and other associated information. For the quarters ended September 30, 2026, and 2025, sales to five major customers accounted for approximately
As of September 30, 2026, and December 31, 2025, the Company had $
11
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
3) Accounts Receivable, net
| September 30, 2026 | December 31, 2025 | |||||||
| Accounts receivable, gross | $ | $ | | |||||
| Less: Allowance for doubtful accounts (current expected credit loss) – see 3.1 below | ( | ) | ( | ) | ||||
| Accounts receivable, net | $ | $ | ||||||
3.1)
| September 30, 2026 | December 31, 2025 | |||||||
| Opening balance | $ | $ | ||||||
| Charge for the period / year | ||||||||
| Adjustment during the period / year | ( | ) | - | |||||
| Closing balance | $ | $ | ||||||
| * | During the quarter ended September 30, 2026, and year ended December 31, 2025, the Company collected nil and $ |
4) Other current assets
| September 30, 2026 | December 31, 2025 | |||||||
| Unbilled revenue | $ | $ | | * | ||||
| Prepaid expenses | ||||||||
| Advance to acquire Teyame and Datono (see note 6[B] for details) | - | |||||||
| Deposits | - | |||||||
| Advance to Healthcare Triangle Private Limited, a related party1 | - | |||||||
| Others | ||||||||
| Total | $ | $ | ||||||
| * | |
| 1 |
5) Advances
| September 30, 2026 | December 31, 2025 | |||||||
| Advance to related party contractor - for AI tools and software development | $ | $ | ||||||
| Advance to related party contractor - for services | ||||||||
| Less: Settlement of advances through equity | ( | ) | - | |||||
| Total advances, net | $ | $ | ||||||
As of September 30, 2026, and December 31, 2025, the advances outstanding are $
| - | $ |
12
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
| - | On June 24, 2026, the Company entered into a Securities Exchange Agreement with SecureKloud pursuant to which certain preferred equity securities held by SecureKloud were exchanged for shares of the Company’s common stock on July 28, 2026, following receipt of stockholder approval. In connection with the July 28, 2026, exchange and extinguishment of the Series B Convertible Preferred Stock, the Company assessed the qualitative nature and integrated terms of its settlement with SecureKloud, a related party, and concluded that settlement of the $ |
| A. | Related party transactions: |
Following are the transactions with related parties during the periods presented:
| Related Parties | Nature of transactions | Quarter ended September 30, 2026 | Quarter ended September 30, 2025 | Nine-months ended September 30, 2026 | Nine-months ended September 30, 2025 | |||||||||||||
| SecureKloud Technologies Limited, India | Services received and paid for | $ | $ | $ | $ | |||||||||||||
| Amounts advanced | - | |||||||||||||||||
| Healthcare Triangle (Pvt.) Limited, India | Services received and paid for | - | - | |||||||||||||||
| Amounts advanced | - | - | - | |||||||||||||||
| SecureKloud Technologies, Inc. | Services received and paid for | - | - | - | ||||||||||||||
| Amounts advanced | - | - | - | |||||||||||||||
| Services rendered | - | - | - | |||||||||||||||
| Amounts collected by related party on behalf of the Company | - | - | ||||||||||||||||
| Rent expenses paid | - | - | ||||||||||||||||
| Blockedge Technologies, Inc. | Services received and paid for | |||||||||||||||||
| Amounts advanced | - | - | ||||||||||||||||
| Revenue | - | - | ||||||||||||||||
| Key management personnel | Remuneration | |||||||||||||||||
| Board of Directors | Compensation | - | - | |||||||||||||||
| Amount advanced | $ | - | $ | - | ||||||||||||||
13
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
6) Goodwill and Other Intangible Assets
| September 30, 2026 | December 31, 2025 | |||||||||
| Goodwill | (see ‘A’ below) | $ | $ | |||||||
| Other intangible assets, net | (see ‘B and C’ below) | $ | $ | |||||||
| A) | On June 16, 2025 (the “Closing date”), Healthcare Triangle, Inc. (the “Company”), through its wholly owned subsidiary QuantumNexis Inc., a Delaware corporation, entered into an Asset and Stock Transfer Agreement (ATA) with Niyama Healthcare Inc., a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”). Pursuant to the ATA, the Company agreed to purchase (i) the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) |
(1) $
The transaction resulted in recognition of goodwill with a carrying value of $
| B) | On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) through its wholly owned subsidiary Teyame AI Holdings Inc., effective January 1, 2026. The aggregate purchase price for the Acquired Companies is up to $ |
The cash consideration includes: (i) $
The equity consideration includes: (a) restricted shares or pre-funded warrants of the Company’s common stock with an agreed value of $
The number of shares of common stock issued as part of the equity consideration, and the number of shares of common stock underlying the preferred stock, were determined by reference to a “Base Price” equal to the average of the volume-weighted average prices (“VWAPs”) of the Company’s common stock for the five trading days immediately prior to the Closing Date, as further defined in the Share Purchase Agreement. The preferred stocks were converted into common stock subsequent to the stockholder approval on July 17, 2026, as contemplated by the Share Purchase Agreement.
14
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
The Share Purchase Agreement also provides for an earnout payable in the Company’s preferred stock to the previous owners of the Acquired Companies, with an aggregate value of up to $
| Purchase consideration | Amount | |||
| Cash paid up to September 30, 2026 | $ | |||
| Purchase consideration payable as of September 30, 2026 | ||||
| Common stock | ||||
| Preferred stock (convertible into common stock at the Company’s option) | ||||
| Earnout consideration | ||||
| Total | $ | |||
The Company is in the process of determining the fair values of the identifiable assets acquired and liabilities assumed as of the acquisition date in accordance with ASC 805, Business Combinations. As the initial accounting for the business combination is incomplete as of the date of these financial statements, the Company has not yet finalized the purchase price allocation. The provisional amounts recognized reflect management’s best estimates based on information available at this time.
The final purchase price allocation, including the determination of fair values of identifiable intangible assets, property and equipment, deferred tax assets and liabilities, and any resulting goodwill, will be completed as soon as practicable and within the measurement period of up to one year from the acquisition date as permitted under ASC 805-10-25-15. Any adjustments to the provisional amounts identified during the measurement period will be recognized in the reporting period in which the adjustment is determined, with a corresponding adjustment to goodwill.
Pending the purchase price allocation, the Company has provisionally recognized an amount of $
| Current assets acquired: | ||||||
| Cash and cash equivalents | $ | |||||
| Accounts receivable, net | ||||||
| Other current assets | ||||||
| Total current assets | $ | |||||
| Non-current assets acquired: | ||||||
| Furniture and equipment, net | $ | |||||
| Operating lease right-of-use assets | ||||||
| Other non-current assets | ||||||
| Total assets acquired | (a) | $ | ||||
| Liabilities assumed: | ||||||
| Accounts payable | $ | |||||
| Operating lease liabilities | ||||||
| Short-term borrowing | ||||||
| Other current liabilities | ||||||
| Total current liabilities | $ | |||||
| Non-current liabilities assumed | ||||||
| Long term debt | ||||||
| Operating long-term lease liabilities | ||||||
| Other non-current liabilities | ||||||
| Total liabilities assumed | (b) | |||||
| Net liabilities assumed | (c = a – b) | $ | ( | ) | ||
| Preliminary intangible assets | (d) | $ | ||||
| Total purchase consideration allocated (pending purchase price allocation) | (c + d) | $ | ||||
15
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
| C) | Other intangible assets |
| September 30, 2026 | December 31, 2025 | ||||||||||||||||||||||||||||||||||
| Useful | Gross | Amortization | Net | Gross | Amortization | Net | |||||||||||||||||||||||||||||
| life | carrying | expense for | Accumulated | carrying | Carrying | expense for | Accumulated | carrying | |||||||||||||||||||||||||||
| (Years) | amount | the period | amortization | amount | amount | the year | amortization | amount | |||||||||||||||||||||||||||
| Intellectual property | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
| Trademark | |||||||||||||||||||||||||||||||||||
| Software | — | — | — | ||||||||||||||||||||||||||||||||
| Intangible assets, total | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
7) Furniture and Equipment
Furniture and equipment consisted of the following:
| September 30, 2026 | December 31, 2025 | |||||||||||||||||||||||||||||||||||
| Useful | Gross | Depreciation | Net | Gross | Depreciation | Net | ||||||||||||||||||||||||||||||
| life | carrying | expense for | Accumulated | carrying | carrying | expense for | Accumulated | carrying | ||||||||||||||||||||||||||||
| (Years) | amount | the period | depreciation | amount | amount | the year | depreciation | amount | ||||||||||||||||||||||||||||
| Furniture and Fixtures | $ | $ | | $ | | $ | $ | | $ | | $ | | $ | | ||||||||||||||||||||||
| Furniture and Fixtures total | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||
During the period ended September 30, 2026, the Company purchased furniture and fixtures amounting to $
8) Right-of-use Assets
The Company determines if an arrangement contains a lease at inception. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.
The Company utilized a portfolio approach in determining the discount rate. The portfolio approach takes into consideration the range of the term, the range of the lease payments, the category of the underlying asset and the Company’s estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. The Company also considered its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating the incremental borrowing rates.
Leases with a term of
ROU Asset:
| September 30, 2026 | December 31, 2025 | |||||||
| Operating right-of-use assets, at cost | $ | $ | - | |||||
| Less: Accumulated amortization (*) | ( | ) | - | |||||
| Operating right-of-use assets, net | $ | $ | - | |||||
| (*) |
16
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
The Company’s principal facility is located in Pleasanton, CA. Lease rental for the quarter and nine months ended September 30, 2026, were $
In addition, the Company acquired right-of-use assets and lease liability as part of the business combination (see note 6[B] for details). The Company acquired right-of-use assets with a cost of $
Lease liability:
Future minimum lease obligations under our non-cancellable lease agreement as of September 30, 2026, and December 31, 2025, are as follows:
| Fiscal Year | September 30, 2026 | December 31, 2025 | ||||||
| Next 12 months | $ | - | ||||||
| 12-24 months | - | |||||||
| Beyond 24 months | - | |||||||
| Total | - | |||||||
| Less: Imputed interest | ( | ) | - | |||||
| Net present value of future minimum lease payments | - | |||||||
| Less: Operating lease liability, current | ( | ) | - | |||||
| Operating lease liability, non-current | $ | - | ||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Operating lease liability, current | $ | - | ||||||
| Operating lease liability, non-current | $ | - | ||||||
17
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
9) Other non-current assets
| September 30, 2026 | December 31, 2025 | |||||||
| Platform development work-in-progress (see note 5) | $ | $ | - | |||||
| Others | - | |||||||
| Total | $ | $ | - | |||||
10) Short-Term Debt
| September 30, 2026 | December 31, 2025 | |||||||
| Recourse financing [refer 10(A) below] | $ | $ | ||||||
| Convertible notes [refer 10(B) and 10(C) below] | ||||||||
| Debt with credit institutions – current [refer 10(D) below] | - | |||||||
| Others | ||||||||
| Total | $ | $ | ||||||
A. Recourse Financing
During 2022, the Company obtained a credit facility from Seacoast Business Funding (SBF), a division of Seacoast National Bank. The funding is against the accounts receivable of the Company and one of its subsidiaries. The maximum amount of advance under the arrangement is $
The SBF facility incurred a factoring interest cost of
In addition, a recently acquired subsidiary of the Company with an acquisition effective date of January 1, 2026, utilizes recourse-based accounts receivable financing arrangement with a number of banks, whereby the subsidiary receives cash against the customer invoices. Under this arrangement, the maximum advance amount available to the subsidiary is $
B. 2025 Convertible Notes
As of December 31, 2025, the 2025 Convertible Notes had a fair value of $
On June 12, 2026, the Company used a portion of the proceeds from the issuance of the 2026 Convertible Notes (see note 10[C]) to settle the remaining obligations under the 2025 Convertible Notes. The remaining liability was remeasured to fair value immediately prior to settlement, and derecognized upon payment of the settlement consideration.
As a result of the repayments, conversions and changes in fair value during the nine months ended September 30, 2026, the Company had no outstanding obligations under the 2025 Convertible Notes as of September 30, 2026.
18
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
The following table represents changes in the fair value of the 2025 Debentures for the periods presented:
| September 30, 2026 | December 31, 2025 | |||||||
| Opening balance - fair value | $ | $ | ||||||
| Less: Debt repayment | ( | ) | - | |||||
| Less: Conversions to equity stock (fair value) | ( | ) | ( | ) | ||||
| Changes in fair value (recognized in earnings) | ( | ) | ||||||
| Closing balance - fair value | $ | - | $ | |||||
C. 2026 Convertible Notes
On June 12, 2026, the Company completed a private placement to unrelated institutional investors of
The Company has the option to prepay the 2026 Debentures at
The Company elected the fair value option for these debentures under ASC 825, Financial Instruments, at initial recognition. Accordingly, the 2026 Debentures are recorded at fair value and remeasured at each reporting date, with changes in fair value recognized in earnings.
The fair value of these debentures is classified within Level 3 of the fair value hierarchy because the valuation uses significant unobservable inputs and management judgment. The Company engaged an independent third-party valuation specialist to estimate the fair value of the debentures using a Monte Carlo simulation model. The valuation model simulated multiple potential future stock-price paths and expected settlement outcomes and incorporated the contractual terms of the instruments, including the variable conversion feature, floor price, maturity, and other debt-specific provisions.
The following table represents changes in the fair value of the 2026 Debentures for the periods presented:
| September 30, 2026 | December 31, 2025 | |||||||
| Fair value at issuance | $ | $ | - | |||||
| Changes in fair value (recognized in earnings) | - | |||||||
| Repayments during the period(2) | ( | ) | ||||||
| Closing balance - fair value | $ | $ | - | |||||
(1) | In connection with the issuance of the 2026 Debentures, the Company incurred expenses amounting to $ |
| (2) |
As of September 30, 2026, significant assumptions used by an independent third-party valuer in the valuation included the Company’s common stock price of $
19
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
D. Debt from credit institutions
Teyame and Datono have secured various credit facilities across multiple financial institutions. As of September 30, 2026, the total available credit facilities and loans amounted to $
| As of | Drawdown | Repayments | As of | |||||||||||||||||||||||||||||||||
| Facility | Interest | Maturity | January 1, | during | during | Less: | September 30, | Short | Long | |||||||||||||||||||||||||||
| Credit institution | type | rate | Conditions | date | 2026 | the period | the period | CTA | 2026 | term | term | |||||||||||||||||||||||||
| Ibercaja multiproducto | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Caixabank | ( | ) | - | |||||||||||||||||||||||||||||||||
| Bankinter | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Bankinter Línea Pago Impuestos | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||
| Bsantander | - | - | - | - | - | |||||||||||||||||||||||||||||||
| BBVA | ( | ) | - | |||||||||||||||||||||||||||||||||
| BBVA Click & Pay | - | |||||||||||||||||||||||||||||||||||
| Caixabank | ( | ) | - | |||||||||||||||||||||||||||||||||
| Abanca | - | |||||||||||||||||||||||||||||||||||
| Unicaja | - | |||||||||||||||||||||||||||||||||||
| Ibercaja Multiproducto Multiempresa | - | |||||||||||||||||||||||||||||||||||
| Targobank | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Deutsche | - | - | ||||||||||||||||||||||||||||||||||
| Bankia | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Bsabadell | - | |||||||||||||||||||||||||||||||||||
| BBVA | ( | ) | ||||||||||||||||||||||||||||||||||
| Bankinter | - | |||||||||||||||||||||||||||||||||||
| Caixabank | - | |||||||||||||||||||||||||||||||||||
| Deutsche | - | |||||||||||||||||||||||||||||||||||
| Ibercaja Multiproducto Multiempresa | - | |||||||||||||||||||||||||||||||||||
| Abanca | - | |||||||||||||||||||||||||||||||||||
| Caixabank | - | - | ||||||||||||||||||||||||||||||||||
| Bankinter | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Bankinter Línea Pago Impuestos | - | - | - | - | ||||||||||||||||||||||||||||||||
| Bsantander | - | - | - | - | - | |||||||||||||||||||||||||||||||
| BBVA | ( | ) | - | |||||||||||||||||||||||||||||||||
| BBVA Click & Pay | - | |||||||||||||||||||||||||||||||||||
| Caixabank | ( | ) | - | - | ||||||||||||||||||||||||||||||||
| Ibercaja | - | |||||||||||||||||||||||||||||||||||
| Deutsche | - | - | ||||||||||||||||||||||||||||||||||
| BBVA | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Deutsche | - | - | ||||||||||||||||||||||||||||||||||
| Caixabank | - | |||||||||||||||||||||||||||||||||||
| Deutsche | - | |||||||||||||||||||||||||||||||||||
20
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
| Fiscal Year | As of September 30, 2026 | As of December 31, 2025 | ||||||
| Next 12 months | $ | $ | - | |||||
| 12-24 months | - | |||||||
| 24-36 months | - | |||||||
| Above 36 months | - | |||||||
| Total | $ | $ | - | |||||
| September 30, 2026 | December 31, 2025 | |||||||
| Current | $ | $ | - | |||||
| Non-current | - | |||||||
| Total | $ | $ | - | |||||
The debt with credit institutions was acquired as part of the Teyame and Datono business combination on January 1, 2026, and represents liabilities assumed at the acquisition date. See also note 6(B).
11) Other current liability
| Particulars | September 30, 2026 | December 31, 2025 | ||||||
| Purchase consideration payable (refer note 6[B]) | $ | $ | - | |||||
| Professional fees payable | - | |||||||
| Unearned revenue | ||||||||
| Commission accrual | ||||||||
| Accrued payroll | ||||||||
| Director’s fees | - | |||||||
| Insurance | - | |||||||
| Others | * | |||||||
| Total | $ | $ | ||||||
| * |
12) Contingent consideration
On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) through its wholly owned subsidiary Teyame AI Holdings Inc., effective January 1, 2026. The aggregate purchase price for the Acquired Companies is up to $
21
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
13) Stockholders’ Equity
All references to the number of common shares and price per Common Stock, for all periods presented, have been adjusted to reflect the following:
| - | one-for-sixty reverse stock-split effective February 10, 2026, and | |
| - | one-for-twenty reverse stock-split effective October 26, 2026, (see note 18). |
These reverse splits reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share. Basic and diluted net loss per share reflect the effect of the reverse stock-splits for all periods presented.
Accordingly, unless indicated otherwise, all the current period and historical per share data, number of shares issued and outstanding, stock awards, and other common stock equivalents for the periods presented in this Report on Form 10-Q have been adjusted retroactively, where applicable, to reflect the reverse stock-split.
The reverse stock-split affected all common stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. The Company issued fractional shares at the participant level in connection with the reverse stock-split. The reverse stock-split did not impact holders of Preferred equity, or the portion of stocks allocated for employee stock options.
A. Common Stock
| i. | Equity Issuance and Pre-Funded Warrants for Business Combination |
On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) through its wholly owned subsidiary Teyame AI Holdings Inc. The aggregate purchase price for the Acquired Companies is up to $
The consideration consists of a cash payout of $
The number of shares of common stock issued as part of the equity consideration, and the number of shares of common stock underlying the preferred stock, were determined by reference to a “Base Price” equal to the average of the volume-weighted average prices (“VWAPs”) of the Company’s common stock for the five trading days immediately prior to the Closing Date, as further defined in the Share Purchase Agreement. The preferred stocks were converted into common stock subsequent to the stockholder approval on July 17, 2026, as contemplated by the Share Purchase Agreement.
During the period ended September 30, 2026, a total of
| ii. | Pre-Funded Warrants |
| ● | On February 26, 2026, the Company completed a registered direct offering pursuant to which it issued and sold an aggregate of |
The Company received net proceeds of approximately $
| ● | In connection with the Equity Purchase Agreement (“ELOC”, see point [D] below), on June 12, 2026, the Company issued Hudson a five-year common stock purchase warrant (“ELOC warrant”) to purchase |
22
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
The movement of warrants during the periods ended September 30, 2026, and 2025, is shown below:
| Weighted | Average | |||||||||||
| Average | Remaining | |||||||||||
| Number of | Exercise | Contractual | ||||||||||
| Warrants | Warrants | price | Term | |||||||||
| Outstanding on January 1, 2026 | $ | |||||||||||
| Granted during the period(*): | ||||||||||||
| Registered direct offering (see note above) | - | |||||||||||
| Pre-funded warrants (Teyame, see note 6[B]) | - | - | ||||||||||
| ELOC warrant (see note above) | - | - | ||||||||||
| Exercised during the period(*) | ( | ) | - | |||||||||
| Outstanding on September 30, 2026 | ||||||||||||
| Exercisable on September 30, 2026 | $ | |||||||||||
| (*) |
| Weighted | ||||||||||||
| Weighted | Average | |||||||||||
| Average | Remaining | |||||||||||
| Number of | Exercise | Contractual | ||||||||||
| Warrants | Warrants | price | Term | |||||||||
| Outstanding on January 1, 2025 | $ | |||||||||||
| Issued during the period(*) | ||||||||||||
| Outstanding on September 30, 2025(*) | ||||||||||||
| Exercisable on September 30, 2025(*) | $ | |||||||||||
| (*) |
B. Preferred Series ‘B’ stock
On July 28, 2026, following stockholder approval, the Company completed the exchange and cancellation of all
Immediately prior to the exchange, the Series ‘B’ Preferred Stock had a carrying amount of approximately $
In evaluating the qualitative nature and integrated terms of the settlement, the Company determined that the $
Total consideration transferred, including the common shares issued and settlement of the advance, was approximately $
For earnings-per-share purposes, the deemed contribution was added to net income (loss) in determining income (loss) available to common stockholders. The common shares issued in the exchange were included in weighted-average common shares outstanding from July 28, 2026, giving retrospective effect to the subsequent reverse stock split.
C. Conversion of Debt to Equity
During the period ended September 30, 2026, the holders of the 2025 Debentures converted a portion of the Debentures into
23
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
D. Equity Financing
During the period ended September 30, 2026, the Company completed several equity financing activities designed to strengthen liquidity, support working capital needs, and fund general corporate and strategic initiatives.
| i. | On February 26, 2026, the Company entered into a securities purchase agreement in connection with a registered direct offering, pursuant to which the Company agreed to sell an aggregate of |
The pre-funded warrants were deemed cashless and were issued in lieu of common stock to certain investors and exercisable immediately for an aggregate of
The Company received net proceeds of approximately $
| ii. | At-The-Market Placements |
During the period ended September 30, 2026, the Company issued shares of its common stock pursuant to its At-the-Market Sales Agreement dated November 18, 2025. The Company sold an aggregate of
| iii. | Equity line of credit (ELOC) |
On June 12, 2026, the Company entered into an Equity Purchase Agreement and a Registration Rights Agreement with Hudson Global Ventures, LLC (“Hudson”). Under the Equity Purchase Agreement, the Company has the right, but not the obligation, to sell to Hudson, from time to time and at the Company’s sole discretion, shares of the Company’s common stock for aggregate gross proceeds of up to $
On July 17, 2026, the Company’s stockholders approved the issuance of common stock in excess of the Nasdaq exchange cap under the Equity Purchase Agreement, in accordance with Nasdaq Listing Rule 5635(d).
On September 22, 2026, the Company amended the Equity Purchase Agreement to reduce the maximum amount per purchase notice from $
The Company’s ability to sell shares under the agreement remains subject to an effective resale registration statement, continued Nasdaq listing, minimum trading-price requirements and other customary conditions. Hudson may not purchase shares to the extent that its beneficial ownership would exceed
In connection with the agreement, the Company issued Hudson a five-year warrant to purchase
During the nine months ended September 30, 2026, the Company completed two draws under the Equity Purchase Agreement, issuing
As of September 30, 2026, the remaining maximum contractual commitment under the Equity Purchase Agreement was approximately $
24
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
14) Segment Information
Schedule of operating segments
| Three months ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Software services | $ | $ | $ | ( | ) | ( | )% | |||||||||
| Managed services and support | ( | ) | ( | )% | ||||||||||||
| Customer engagement services (*) | - | % | ||||||||||||||
| All others | % | |||||||||||||||
| Revenue | $ | $ | $ | % | ||||||||||||
| (*) |
| Nine months ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Software services | $ | $ | $ | ( | ) | ( | )% | |||||||||
| Managed services and support | ( | ) | ( | )% | ||||||||||||
| Customer engagement services (*) | - | % | ||||||||||||||
| All others | - | - | % | |||||||||||||
| Revenue | $ | $ | $ | % | ||||||||||||
| (*) |
Operating Results by Operating Segment
During the three months ended September 30, 2026, the Company refined and simplified the presentation of its segment disclosures in accordance with ASC 280, Segment Reporting, to better align with the financial information regularly provided to its Chief Operating Decision Makers (“CODMs”) for evaluating operating performance and allocating resources.
The revised presentation focuses on reportable segment revenues, the measure of segment profit or loss used by the CODMs and other disclosures required under ASC 280. Amounts previously presented under “Corporate and Others” have been reclassified, as applicable, to “All others” non-reportable business activities or unallocated corporate reconciling items, as corporate activities do not constitute a reportable operating segment.
25
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
Comparative segment information for the three and nine months ended September 30, 2025, has been reclassified to conform to the current-period presentation. These changes have no impact on the Company’s previously reported consolidated financial position, results of operations or cash flows.
| Three months ended September 30, 2026 | ||||||||||||||||||||||||||||
| Software | Managed | Customer Engagement | All | Total Reportable | Corporate and other | Consolidated | ||||||||||||||||||||||
| Services | Services | Services* | others | Segments | items | Total | ||||||||||||||||||||||
| Revenue | $ | - | ||||||||||||||||||||||||||
| Cost of revenue | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | - | ( | ) | |||||||||||||||
| Sales and marketing | ( | ) | ( | ) | ( | ) | - | ( | ) | ( | ) | ( | ) | |||||||||||||||
| General and administrative | ( | ) | ( | ) | ( | ) | - | ( | ) | ( | ) | ( | ) | |||||||||||||||
| Others, net | ( | ) | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
| Profit / (loss) before income taxes | $ | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | |||||||||||||||||
| (*) | represents segment acquired as part of business combination. See note 6(B) for details. |
| Nine months ended September 30, 2026 | ||||||||||||||||||||||||||||
| Software Services | Managed Services | Customer Engagement Services* | All others | Total Reportable Segments | Corporate and other items | Consolidated Total | ||||||||||||||||||||||
| Revenue | $ | - | ||||||||||||||||||||||||||
| Cost of revenue | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | - | ( | ) | |||||||||||||||
| Sales and marketing | ( | ) | ( | ) | ( | ) | - | ( | ) | ( | ) | ( | ) | |||||||||||||||
| General and administrative | ( | ) | ( | ) | ( | ) | - | ( | ) | ( | ) | ( | ) | |||||||||||||||
| Others, net | ( | ) | - | ( | ) | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||
| Profit / (loss) before income taxes | $ | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | |||||||||||||||||
| (*) | represents segment acquired as part of business combination. See note 6(B) for details. |
| Three months ended September 30, 20251 | ||||||||||||||||||||||||
| Software Services | Managed Services | All others | Total Reportable Segments | Corporate and other items | Consolidated Total | |||||||||||||||||||
| Revenue | $ | - | ||||||||||||||||||||||
| Cost of revenue | ( | ) | ( | ) | ( | ) | ( | ) | - | ( | ) | |||||||||||||
| Sales and marketing | ( | ) | ( | ) | - | ( | ) | ( | ) | ( | ) | |||||||||||||
| General and administrative | ( | ) | ( | ) | - | ( | ) | ( | ) | ( | ) | |||||||||||||
| Others, net | - | - | - | - | ||||||||||||||||||||
| Profit / (loss) before income taxes | $ | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | |||||||||||||
| (1) |
26
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
| Nine months ended September 30, 20251 | ||||||||||||||||||||||||
| Software Services | Managed Services | Others | Total Reportable Segments | Corporate and other items | Consolidated Total | |||||||||||||||||||
| Revenue | $ | - | ||||||||||||||||||||||
| Cost of revenue | ( | ) | ( | ) | ( | ) | ( | ) | - | ( | ) | |||||||||||||
| Sales and marketing | ( | ) | ( | ) | - | ( | ) | ( | ) | ( | ) | |||||||||||||
| General and administrative | ( | ) | ( | ) | - | ( | ) | ( | ) | ( | ) | |||||||||||||
| Others, net | - | - | - | - | ||||||||||||||||||||
| Profit / (loss) before income taxes | $ | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | |||||||||||||
| (1) | Comparatives have been rearranged for the purposes of comparison. |
Revenue from top 5 customers
Schedule of concentration
| Three months ended September 30, 2026 | Nine months ended September 30, 2026 | |||||||||||||||
| Customer | Amount | % of Revenue | Amount | % of Revenue | ||||||||||||
| Customer 1 | $ | % | $ | % | ||||||||||||
| Customer 2 | % | % | ||||||||||||||
| Customer 3 | % | % | ||||||||||||||
| Customer 4 | % | % | ||||||||||||||
| Customer 5 | $ | % | $ | % | ||||||||||||
| (*) | represents customer acquired as part of business combination. See note 6(B) for details. |
| Three months ended September 30, 2025 | Nine months ended September 30, 2025 | |||||||||||||||
| Customer | Amount | % of Revenue | Amount | % of Revenue | ||||||||||||
| Customer 1 | $ | % | $ | % | ||||||||||||
| Customer 2 | % | % | ||||||||||||||
| Customer 3 | % | % | ||||||||||||||
| Customer 4 | % | % | ||||||||||||||
| Customer 5 | $ | % | $ | % | ||||||||||||
| (*) | represents customer acquired as part of business combination. See note 6(B) for details. |
27
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
15) Legal Matters
On 13 August 2026, L1 Capital Global Opportunities Master Fund Ltd filed proceedings against the Company in the Grand Court of the Cayman Islands (FSD 257 of 2026). It seeks declarations that the exercise price of, and the number of shares issuable under, its warrant dated 28 December 2023 have been adjusted. The proceedings were served on the Company on 19 October 2026 and are at an early stage, and no hearing of the claim has taken place. The Company has instructed Cayman Islands counsel and is taking legal advice.
All legal costs are expensed as incurred.
16) Stock Based Compensation
| September 30, 2026 | December 31, 2025 | |||||||
| Opening share options outstanding | ||||||||
| Vested / granted during the period / year | - | |||||||
| Forfeited / expired | - | - | ||||||
| Closing share options outstanding | ||||||||
Schedule of stock option activity
The employee options balance available under the plan (for issuance) were
There were no unvested options outstanding as of September 30, 2026.
The following table summarizes the activities for our unvested options for the period ended September 30, 2025.
| Number of | Weighted average Grant Date Fair Value | |||||||
| Shares | Per Share | |||||||
| Unvested on January 1, 2025 | - | - | ||||||
| Granted | ||||||||
| Vested | ( | ) | ||||||
| Unvested on September 30, 2025 | - | - | ||||||
17) Income / (loss) per share
| Three months ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net profit / (loss) attributable to common stockholders | $ | (*) | $ | ( | ) | |||
| Weighted average shares outstanding used in basic EPS computations | ||||||||
| Weighted average shares outstanding used in diluted EPS computations | - | |||||||
| Basic EPS – Stockholders | $ | $ | ( | ) | ||||
| Diluted EPS – Stockholders | $ | $ | ( | ) | ||||
| (*) |
28
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
| Nine months ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net loss attributable to common stockholders | $ | ( | )(1) | $ | ( | ) | ||
| Weighted average shares outstanding used in basic per common share computations | ||||||||
| Basic / Diluted EPS – Stockholders(*) | $ | ( | ) | $ | ( | ) | ||
| (*) |
| (1) |
18) Subsequent Events
| i. | The Company effected a one-for-twenty reverse stock-split of its issued and outstanding common stock on October 26, 2026. The reverse split reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share. Basic and diluted net loss per share reflect the effect of the reverse stock-split for all periods presented. |
| ii. | Subsequent to September 30, 2026, the Company continued to advance its previously announced plan to separate Teyame AI Holdings Inc., a consolidated subsidiary of the Company, and pursue a direct listing of its common stock. In connection with the proposed separation, Teyame AI Holdings Inc. intends to file a registration statement on Form 10 with the Securities and Exchange Commission to register its common stock under the Securities Exchange Act of 1934. The proposed transaction is expected to include a distribution of a portion of Teyame AI Holdings Inc.’s outstanding common stock to the Company’s stockholders, with the Company retaining a controlling ownership interest in Teyame AI Holdings Inc. following the distribution. The proposed separation, distribution and direct listing remain subject to completion of the Form 10 registration process, applicable regulatory and stock exchange requirements, final corporate approvals and other customary conditions. Accordingly, there can be no assurance as to the timing or completion of the proposed transaction. | |
| iii. | Effective October 1, 2026, the Company initiated a strategic realignment of its U.S. operations through Purpose Health Inc., its wholly owned subsidiary. As part of this transition, certain U.S. customer contracts and related business development, project support and service delivery activities are being transferred to Purpose Health Inc., while certain corporate and administrative functions will continue to be managed by the Company. The transition is being implemented through applicable intercompany agreements and customer and vendor arrangements. As Purpose Health Inc. remains a wholly owned consolidated subsidiary, the internal restructuring is not expected to have a material impact on the Company’s consolidated financial position or results of operations. | |
| iv. | Subsequent to September 30, 2026, the Company issued an aggregate of | |
| v. | See note 15, Legal Matters, for developments after September 30, 2026, in the proceedings initiated by L1 Capital Global Opportunities Master Fund Ltd. (“L1 Capital”) against the Company. |
| vi. | On October 1, 2026, the Company received a Staff Delisting Determination from The Nasdaq Stock Market LLC (“Nasdaq”) due to noncompliance with the minimum bid price requirement of $ |
On October 8, 2026, the Company requested a hearing before the Nasdaq Hearings Panel to appeal the determination. The appeal stayed the suspension of trading and delisting proceedings pending the Panel’s decision.
29
HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements
(Unaudited)
(In thousands except share and per share data)
On October 26, 2026, the Company completed a one-for-twenty reverse stock split of its common stock as part of its efforts to regain compliance with Nasdaq’s minimum bid price requirement. As a result, every twenty outstanding common shares were consolidated into one share. The Company’s trading symbol remains “HCTI.”
The Company continues to pursue its appeal and engage with Nasdaq regarding its continued listing. On November 5, 2026, the Company and its advisors presented its case before the Nasdaq Hearings Panel and it is awaiting that Panel’s decision.
19) New Accounting Pronouncements
| A. | Implemented |
| In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendments in this update provide a practical expedient permitting an entity to assume that conditions at the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current classified accounts receivable and contract assets. We adopted this ASU on a prospective basis effective January 1, 2026. While this ASU was adopted, we did not elect practical expedient permitted under this ASU. Therefore, the adoption has no impact on our consolidated financial statements. |
| B. | Not Yet Due |
| i. | ASU No. 2025-06. In September 2025, the FASB issued ASU No. 2025-06, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software,” which is intended to modernize internal-use software guidance by removing all references to project stages and by clarifying the thresholds entities apply to begin capitalizing costs. ASU No. 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted. The guidance can be applied on a prospective basis, a modified basis for in-process projects, or a retrospective basis. We are currently evaluating the impact of the standard on our consolidated financial statements. |
| ii. | ASU No. 2024-03. In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,” which is intended to improve disclosures about a public business entity’s expenses by requiring disaggregated disclosure, in the notes to the financial statements, of prescribed categories of expenses within relevant income statement captions. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The new standard may be applied either on a prospective or retrospective basis. We are currently evaluating the impact of the standard on our consolidated financial statement disclosures. |
Recent accounting pronouncements adopted or pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.
30
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion summarizes the significant factors affecting the operating results, financial condition, liquidity, and cash flow of our Company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and the related notes thereto, and the consolidated financial statements and the related notes thereto all included elsewhere in this Quarterly Report on Form 10-Q. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity, and capital resources, and all other non-historical statements in this discussion are forward-looking statements and are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this report, and in the section entitled “Note About Forward-Looking Statements” contained in this Quarterly Report on Form 10-Q, and in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”).
Overview
Healthcare Triangle, Inc. (the “Company”) is a leading healthcare information technology company focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the Healthcare and Life Sciences industry.
The Company was formed on October 29, 2019, as a Nevada corporation and converted into a Delaware corporation on April 24, 2020, to provide IT and data services to the Healthcare and Life Sciences (“HCLS”) industry. The business commenced on January 1, 2020, after SecureKloud Technologies Inc. transferred its Life Sciences business to us.
On June 16, 2025, the Company, through its wholly owned subsidiary QuantumNexis Inc., a Delaware corporation, entered into an Asset and Stock Transfer Agreement (ATA) with Niyama Healthcare Inc., a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”). Pursuant to the ATA, the Company purchased (i) the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) 100% shareholder equity interest in Ezovion Solutions Private Limited, Chennai, India - a Hospital Information Systems SaaS Provider in exchange for a Purchase Price.
Effective January 1, 2026, the Company, through its wholly owned subsidiary Teyame AI Holdings Inc., a Delaware corporation, acquired Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) (see note 6[B] for details). Together, Teyame and Datono operate as an integrated platform providing AI-powered omnichannel customer experience, marketing, financial and insurance distribution services.
Teyame leverages its technology solutions to provide customer engagement services that combine artificial intelligence, telemarketing, and contact center operations to support customer acquisition, retention, and service. Its platform enables enterprises particularly in financial services, insurance, and healthcare to manage end-to-end customer interactions across multiple channels.
Datono complements this platform as an insurance brokerage entity, facilitating the marketing and sales of insurance products. Together, the companies form a vertically integrated model combining customer acquisition technology with distribution capabilities, particularly in regulated sectors such as insurance.
As of September 30, 2026, we had a total of 38 full-time employees and 24 sub-contractors, including 30 certified cloud engineers, 11 Epic Certified EHR experts, 6 MEDITECH Certified EHR experts, 11 Admin full-time and 4 Admin sub-contractors. Many of the senior management team and the members of our board of directors hold advanced degrees and some are leading experts in the field of technology, investment banking and public markets.
During the period ended September 30, 2026, the Company effected a 1-for-60 reverse split of its issued and outstanding common stock on February 10, 2026, and subsequent to the end of the period, the Company effected a 1-for-20 reverse split of its issued and outstanding common stock on October 26, 2026. Each reverse split reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share.
Our approach leverages our proprietary technology platforms, extensive industry knowledge, and healthcare domain expertise to provide solutions and services that reinforce healthcare progress. Through our platform, solutions, and services, we support healthcare delivery organizations, healthcare insurance companies, pharmaceutical, and Life Sciences, biotech companies, and medical device manufacturers in their efforts to improve data management, develop analytical insights into their operations, and deliver measurable clinical, financial, and operational improvements.
We offer a comprehensive suite of software, solutions, platforms, and services that enables some of the world’s leading healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to real-world evidence, and accelerate their digital transformation. We combine our expertise in the healthcare technology domain, cloud technologies, DevOps and automation, data engineering, advanced analytics, security, compliance, and governance to deliver platforms and solutions that drive improved results in the complex workflows of Life Sciences, biotech, healthcare providers, and payers. Our differentiated solutions, enabled by our intellectual property and delivered as a service, provide advanced analytics, data science applications, and data aggregation in these highly regulated environments in a more compliant, secure, and cost-effective manner to our customers.
31
Our deep expertise in healthcare technology allows us to reinforce our clients’ progress by accelerating their innovation. Our healthcare IT services include Electronic Health Records (EHR) and software implementation, optimization, extension to community partners, as well as application managed services, and backup and disaster recovery capabilities on public cloud. Our 24x7 managed services are used by hospitals and health systems, payers, Life Sciences, and biotech organizations in their effort to improve health outcomes and deliver deeper, more meaningful patient and consumer experiences. Through our services, our customers achieve a return on investment in their technology by delivering measurable improvements. Combined with our software and solutions, our services provide clients with an end-to-end partnership for their technology innovation.
Our Business Model
The majority of our revenue is generated by the AI powered Customer Engagement segment following the Company’s acquisition of Teyame and Datono effective January 1, 2026, followed by the revenue earned through our full time employees who provide Software Services and Managed Services and Support to our clients in the Healthcare and Life Sciences industry. Our Software Services include strategic advisory, implementation and development services, and Managed Services and Support include post implementation support and cloud hosting.
Key Factors of Success
We believe that our future growth, market adoption, success, and the long-term value creation associated with Teyame and Datono acquisition through our wholly-owned subsidiary Teyame AI Holdings Inc., will depend on several strategic, operational and technological factors. These factors represent significant opportunities that management must successfully address in order to realize the expected benefits of the acquisition and accelerate the combined company’s growth trajectory.
Investment in scaling the business
We need to continuously invest in sales, and marketing to promote our solutions to new and existing customers in various geographies, and other operational and administrative functions in systems, controls and governance to support our expected growth and our transition into a public company. We anticipate that our employee strength will increase over time because of such investments.
On June 16, 2025 (the “Closing date”), Healthcare Triangle, Inc. (the “Company”), through its wholly owned subsidiary QuantumNexis Inc., a Delaware corporation, entered into an Asset and Stock Transfer Agreement (the “Agreement”) with Niyama Healthcare, Inc., a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”). Pursuant to the Agreement, the Company agreed to purchase from the Seller (i) the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) the Seller’s 100% shareholder equity interest in Ezovion Solutions Private Limited, Chennai, India - Hospital Information Systems SaaS Provider as Seller’s Equity (the “Transferred Equity”), as a whole and as a going concern in exchange for the Purchase Price (as defined below).
The total fair value of consideration transferred on the Acquisition Date was approximately $6,095, consisting of the following:
| ● | Cash paid at closing and within 120 days after closing: $1,494 | |
| ● | Fair value of equity consideration: $4,601 | |
| ● | Fair value of contingent consideration (earn-out): $0 |
The deferred cash payment was discounted to present value using a market-based discount rate. The earn-out has been provisionally valued at nil based on initial probability-weighted revenue forecasts.
On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) through its wholly owned subsidiary Teyame AI Holdings Inc., effective January 1, 2026. The aggregate purchase price for the Acquired Companies is up to $50,000, subject to the terms and conditions set forth in the Share Purchase Agreement. The consideration consists of a cash payout of $15,000, with the balance settled through issuance of a combination of the Company’s common stock, preferred stock, with an additional earnout component payable in the Company’s preferred stock upon achievement of specified post-closing performance targets.
The cash consideration includes: (i) $3,000 paid during 2025 pursuant to an advance agreement dated December 3, 2025, (ii) $6,000 paid during January 2026, (iii) $3,200 paid during April 2026, (iv)$1,400 paid during September 2026, and (v) $1,400 payable on the earlier of the conditions being met as outlined in the Share Purchase Agreement, or nine months from the date of the Share Purchase Agreement (but in no event prior to April 29, 2026).
32
The equity consideration includes: (a) restricted shares or pre-funded warrants of the Company’s common stock with an agreed value of $12,000, and (b) a series of the Company’s preferred stock with an agreed value of $18,000 that is convertible into the Company’s common stock, subject to stockholders’ approval. During the period ended September 30, 2026, a total of 488,703 shares of common equity (9,774,055 shares prior to the reverse split of 1:20 effected on October 26, 2026), were issued towards the full settlement of the equity component of purchase consideration of $12,000 and $18,000 respectively.
The number of shares of common stock issued as part of the equity consideration, and the number of shares of common stock underlying the preferred stock, were determined by reference to a “Base Price” equal to the average of the volume-weighted average prices (“VWAPs”) of the Company’s common stock for the five trading days immediately prior to the Closing Date, as further defined in the Share Purchase Agreement. The preferred stocks were converted into common stock subsequent to the stockholder approval on July 17, 2026 as contemplated by the Share Purchase Agreement.
The Share Purchase Agreement also provides for an earnout payable in the Company’s preferred stock to certain key management employees of the Acquired Companies, with an aggregate value of up to $5,000, subject to achievement of specified annual targets as outlined in the Share Purchase Agreement.
| Purchase consideration | Amount | |||
Cash paid up to September 30, 2026 | $ | 13,600 | ||
| Purchase consideration payable as of September 30, 2026 | 1,400 | |||
| Common stock | 12,000 | |||
| Preferred stock (convertible into common stock) | 18,000 | |||
| Earnout consideration | 5,000 | |||
| Total | $ | 50,000 | ||
The Company is in the process of determining the fair values of the identifiable assets acquired and liabilities assumed as of the acquisition date in accordance with ASC 805, Business Combinations. As the initial accounting for the business combination is incomplete as of the date of these financial statements, the Company has not yet finalized the purchase price allocation. The provisional amounts recognized reflect management’s best estimates based on information available at this time.
The final purchase price allocation, including the determination of fair values of identifiable intangible assets, property and equipment, deferred tax assets and liabilities, and any resulting goodwill, will be completed as soon as practicable and within the measurement period of up to one year from the acquisition date as permitted under ASC 805-10-25-15. Any adjustments to the provisional amounts identified during the measurement period will be recognized in the reporting period in which the adjustment is determined, with a corresponding adjustment to goodwill.
33
Pending the purchase price allocation, the Company has provisionally recognized an amount of $53,547 as of January 1, 2026, as follows:
| Current assets acquired: | ||||||
| Cash and cash equivalents | $ | 2 | ||||
| Accounts receivable, net | 4,998 | |||||
| Other current assets | 650 | |||||
| Total current assets | $ | 5,650 | ||||
| Non-current assets acquired: | ||||||
| Furniture and equipment, net | $ | 1,494 | ||||
| Operating lease right-of-use assets | 1,419 | |||||
| Other non-current assets | 206 | |||||
| Total assets acquired | (a) | $ | 8,769 | |||
| Liabilities assumed: | ||||||
| Accounts payable | $ | 2,874 | ||||
| Operating lease liabilities | 749 | |||||
| Short-term borrowing | 5,659 | |||||
| Other current liabilities | 1,875 | |||||
| Total current liabilities | $ | 11,157 | ||||
| Non-current liabilities assumed | ||||||
| Long term debt | 367 | |||||
| Operating long-term lease liabilities | 646 | |||||
| Other non-current liabilities | 146 | |||||
| Total liabilities assumed | (b) | 12,316 | ||||
| Net liabilities assumed | (c = a – b) | $ | (3,547 | ) | ||
| Preliminary intangible assets | (d) | $ | 53,547 | |||
| Total purchase consideration allocated (pending purchase price allocation) | (c + d) | $ | 50,000 | |||
Successful Integration of Teyame into the Healthcare Triangle
A critical factor to the success of the acquisition will be Healthcare Triangle’s ability to effectively integrate Teyame’s operations, technology platforms, people, and the go-to-market strategy into HCTI’s broader healthcare operations. The integration process includes aligning product development roadmap, simplifying operational processes, consolidating administrative functions, and creating a combined portfolio of customer impacting solutions.
Healthcare Triangle expects the acquisition to enhance its capabilities in artificial intelligence-driven healthcare technologies, automation, data analytics, and intelligent workflow management. Successful integration will depend on maintaining operational continuity, retaining key personnel and customers, and minimizing disruptions during the transition period.
In addition, the integration of Teyame’s AI-driven capabilities with HCTI’s cloud infrastructure, data platforms, and healthcare technology services is expected to create cross-functional synergies that may improve scalability, customer engagement, and long-term recurring revenue opportunities.
Cross-selling and customer expansion opportunities
The acquisition enables Healthcare Triangle to cross-sell Teyame’s solutions into its existing customer base while simultaneously introducing HCTI’s broader portfolio of cloud, cybersecurity, managed services and data engineering to Teyame’s customers.
These combined customer relationships may increase enterprise engagements and enhance our data, analytics and automation offerings. Healthcare organizations increasingly prefer integrated technology partners capable of delivering end-to-end digital transformation solutions, and the acquisition may strengthen HCTI’s ability to provide such comprehensive offerings.
Future growth will depend on the Company’s ability to execute coordinated sales and marketing initiatives, demonstrate measurable value to customers, and maintain high customer retention and satisfaction levels.
34
Adoption of Artificial Intelligence (AI) and enhancement of our Healthcare Technology capabilities
The acquisition of Teyame is expected to accelerate the pace of innovation and strengthen HCTI’s strategic position within the rapidly growing healthcare artificial intelligence market. Through the acquisition, HCTI intends to expand its scalable AI-driven capabilities and enhance its portfolio of solutions focused on clinical workflow optimization, patient engagement, operational efficiency, predictive analytics, and intelligent automation.
As healthcare organizations increasingly adopt AI-enabled technologies to improve clinical outcomes, care delivery, streamline operations, and enhance decision-making, HCTI believes the combined technology solutions will support the expansion of differentiated service offerings across hospitals, health systems, and life sciences organizations. The acquisition is also expected to enhance HCTI’s ability to integrate advanced analytics, automation, and data-driven intelligence into its broader healthcare technology ecosystem.
The Company’s future success will depend on its ability to continuously enhance product functionality, maintain technological relevance in a rapidly evolving healthcare environment, and deliver measurable clinical, operational, and financial outcomes for customers. HCTI believes these capabilities will be important drivers of customer adoption, long-term retention, recurring revenue growth, and overall market expansion.
Adoption of our solutions by new and existing customers
We believe that our ability to increase our customer base will enable us to drive growth. Most of our customers initially deploy our solutions within a division or geography and may only initially deploy a limited set of our available solutions. Our future growth is dependent upon our existing customers’ continued success and renewals of our solutions agreements, deployment of our solutions to additional divisions or geographies, and the purchase of subscriptions to additional solutions. Our growth is also dependent on the adoption of our solutions by new customers. Our customers are large organizations who typically have long procurement cycles which may lead to declines in the pace of our new customer additions.
Subscription services adoption
The key factor to our success in generating substantial recurring subscription revenues in future will be our ability to successfully market and persuade new customers to adopt our Software as a Service (“SaaS”) offerings. We are in the early stages of marketing our SaaS offerings such as DataEz, CloudEz and Readabl.AI, and do not yet have enough information about our competition or customer acceptance to determine whether or not recurring subscription revenue from these offerings will have a material impact on our revenue growth.
Mix of solutions and software services revenues
Another factor to our success is the ability to sell our solutions to the existing software services customers. During the initial period of deployment by a customer, we generally provide a greater number of services including advisory, implementation and training. At the same time, many of our customers have historically purchased our solutions after the deployment. Hence, the proportion of total revenues for a customer associated with software services is relatively high during the initial deployment period. While our software services help our customers achieve measurable improvements and make them stickier, they have lower gross margins than solution-based revenue. Over time, we expect the revenues to shift towards recurring and subscription-based revenues.
35
Components of Results of Operations
Revenues
During the quarters ended September 30, 2026, and 2025, the Company generated revenues of approximately $9.12 million compared to revenue of $3.49 million respectively, which represents an increase of $5.63 million or 161% compared to the previous year comparative quarter.
We provide our services and manage our business under these operating segments:
| ● | Software Services | |
| ● | Managed Services and Support | |
| ● | Customer Engagement Services | |
| ● | All others |
Software Services
The Company earns revenue primarily through the sale of software services that is generated from providing strategic advisory, implementation, and development services. The Company enters into Statement of Work (SOW) which provides for service obligations that need to be fulfilled as agreed with the customer. The majority of our software services arrangements are billed on a time and materials basis, and revenues are recognized over time based on time incurred and contractually agreed upon rates. Certain software services revenues are billed on a fixed fee basis and revenues are typically recognized over time as the services are delivered based on time incurred and customer acceptance. We recognize revenue when we have the right to invoice the customer using the allowable practical expedient under ASC 606-10-55-18 since the right to invoice the customer corresponds with the performance obligations completed.
Managed Services and Support
Managed Services and Support include post implementation support and cloud hosting. Managed Services and Support are a distinct performance obligation. Revenue for Managed Services and Support is recognized ratably over the life of the contract.
Customer Engagement Services
The Customer Engagement Services segment, acquired through business combination (see note 6), provides customer search, marketing, telemarketing and customer-support services to financial institutions, insurance companies and intermediaries, and other customers. These services include the promotion and distribution of banking, credit and insurance products; outbound and inbound telemarketing; lead generation and customer-search campaigns; appointment setting; customer service and satisfaction surveys; and technology-enabled digital marketing and customer-interaction services supporting customers’ digital search and customer-care strategies.
The Company recognizes revenue from Customer Engagement Services in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when or as the Company satisfies its performance obligations by transferring the promised services to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services.
Under these arrangements, the Company generally performs the customer-engagement services using its own personnel, processes, systems and operational infrastructure and is primarily responsible for fulfilling the promised services in accordance with contractual requirements and applicable quality standards. The Company has determined that it controls the specified services before they are transferred to the customer and, accordingly, acts as the principal in these arrangements and recognizes revenue on a gross basis.
Consideration under Customer Engagement Services arrangements is generally based on either a fee for each completed and validated outcome or an agreed hourly rate for services provided.
For success-based arrangements, revenue is recognized at a point in time when the applicable contractual outcome has been completed and validated by the customer in accordance with contractual terms. To the extent such consideration is variable, revenue is recognized only to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur.
36
For hourly service arrangements, revenue is recognized over time as the services are performed because the customer simultaneously receives and consumes the benefits of the Company’s performance. Revenue is measured based on the contracted hourly rate and the actual hours of service provided during the applicable reporting period.
Revenue is presented net of estimated cancellations, penalties and other adjustments to the extent such amounts represent adjustments to the transaction price under the applicable customer contracts.
All others
This segment includes Platform Services revenue. A typical Platform Services contract would provide for some or all of the following types of services being provided to the customer: Data Analytics, Backup and Recovery, through our Platform with contract terms unique to each customer. The Company delivers Platform Services through its proprietary platform. Where third-party technology or infrastructure is included in the arrangement, the Company evaluates whether it is acting as principal or agent based on whether it controls the service before transfer to the customer.
The revenue from Platform services is a distinct performance obligation and recognized based on SSP. During the periods presented the Company generated revenue from Platform services on a fixed-price solutions delivery model. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract’s total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized in full in the period in which the loss becomes probable and estimable.
Our contractual terms and conditions for revenue mandate that our services are documented and subject to inspection, testing at the time of delivery to customer. In addition, the Company needs to integrate seamlessly into the customers’ systems. Also, the customer has a right to cancel all, or part of the services rendered if it is not in accordance with statement of work and within the stipulated time.
Cost of Revenue
Cost of revenue consists primarily of employee-related costs associated with the rendering of our services, including salaries, benefits and stock-based compensation expense, the cost of subcontractors, travel costs, cloud hosting charges and allocated overhead the cost of providing professional services is significantly higher as a percentage of the related revenues than for our subscription services due to the direct labor costs and costs of subcontractors. Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue-generating activities.
While we may grow our headcount overtime to capitalize on our market opportunities, we believe our increased investment in automation, electronic health record integration capabilities, and economies of scale in our operating model, will position us to grow our platform solutions revenue at a greater rate than our cost of revenue.
Gross Margin
The gross margin generated by the Company has increased to 23% in the quarter ended September 30, 2026, as compared to 18% in the quarter ended September 30, 2025, respectively.
The Customer Engagement Services segment generated $1.82 million in segment gross profit at a gross margin of approximately 28%, above the Company’s historical margin profile. The continued strength of this segment was the single largest driver of the Company’s overall gross margin expansion, to 23% in the quarter ended September 30, 2026, from 18% in the quarter ended September 30, 2025.
Going forward, we expect the gross margin to continue to increase, as new contracts are being negotiated at higher margins and as a result, we expect future profit margins to increase materially over the next few quarters.
Operating Expenses
Research and Development
Research and development expense (majorly our investment in innovation) consists primarily of employee-related expenses, including salaries, benefits, incentives, employment taxes, severance, and equity compensation costs for our software developers, engineers, analysts, project managers, and other employees engaged in the development and enhancement of our cloud-based platform applications. Research and development expenses also include certain third-party consulting fees. Our research and development expense excludes any depreciation and amortization.
We expect to continue our focus on developing new product offerings and enhancing our existing product offerings. As a result, we expect our future research and development expense to increase in absolute dollars, although it may vary from period to period as a percentage of revenue.
37
Sales and Marketing
Sales and marketing expense consists primarily of employee-related expenses, including salaries, benefits, commissions, travel, discretionary incentive compensation, employment taxes, severance, and equity compensation costs for our employees engaged in sales, sales support, business development, and marketing. Sales and marketing expense also includes operating expenses for marketing programs, research, trade shows, and brand messages, and public relations costs.
We expect our future sales and marketing expenses to continue to increase in absolute dollar terms as we strategically invest to expand our business, although it may vary from period to period as a percentage of total revenues.
General and Administrative
Our general and administrative expenses consist primarily of employee-related expenses including salaries, benefits, discretionary incentive compensation, employment taxes, severance, and stock-based compensation expenses, for employees who are responsible for management information systems, administration, human resources, finance, legal, and executive management. The general and administrative expenses also include occupancy expenses (including rent, utilities, and facilities maintenance), professional fees, consulting fees, insurance, travel, contingent consideration, transaction costs, integration costs, and other expenses. Our general and administrative expenses exclude depreciation and amortization.
In the nearest future, we expect our general and administrative expenses to continue to increase to support business growth. Over the long term, we expect general and administrative expenses to decrease as a percentage of revenue.
Depreciation and Amortization Expenses
Our depreciation and amortization expense consists primarily of depreciation of fixed assets, amortization of customer relationship and capitalized software development costs, and amortization of intangible assets. We expect our depreciation and amortization expense to increase as we continue to invest and expand our business organically and through acquisitions.
Other Income (Expense), Net
Other income (expense), net consists of finance cost and gains or losses on foreign currency.
Deferred Revenues
Advanced billings to clients in excess of revenue earned are recorded as deferred revenue until the revenue recognition criteria are met.
Results of Operations
The following tables set forth selected unaudited condensed consolidated statements of operations and comprehensive loss data and such data as a percentage of total revenues for each of the periods indicated:
| Quarter ended September 30, | ||||||||||||||||
| 2026 | % Sales | 2025 | % Sales | |||||||||||||
| Revenue | $ | 9,116 | 100 | % | $ | 3,489 | 100 | % | ||||||||
| Less: | ||||||||||||||||
| Cost of revenue (exclusive of depreciation /amortization) | 7,035 | 77 | % | 2,871 | 82 | % | ||||||||||
| Sales and marketing | 1,538 | 17 | % | 1,022 | 29 | % | ||||||||||
| General and administrative | 2,213 | 24 | % | 2,085 | 60 | % | ||||||||||
| Research and development | 231 | 3 | % | 59 | 2 | % | ||||||||||
| Bad debts expense / (reversal) | 26 | - | % | (20 | ) | (1 | )% | |||||||||
| Depreciation and amortization | 74 | 1 | % | 63 | 2 | % | ||||||||||
| Other income | (190 | ) | (2 | )% | (731 | ) | (21 | )% | ||||||||
| Changes in fair value | 629 | 7 | % | - | - | % | ||||||||||
| Interest expense | 80 | 1 | % | 32 | 1 | % | ||||||||||
| Forex loss | 26 | - | % | 14 | - | % | ||||||||||
| Loss before income tax | $ | (2,546 | ) | (28 | )% | $ | (1,906 | ) | (55 | )% | ||||||
38
Revenue from operations
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Revenue | $ | 9,116 | $ | 3,489 | $ | 5,627 | 161 | % | ||||||||
Revenue increased by $5.63 million, or 161%, to $9.12 million for the quarter ended September 30, 2026, as compared to $3.49 million for the quarter ended September 30, 2025. Revenue from Customer Engagement Services, and All others increased in the current quarter, while revenue from Software Services and Managed Services and Support decreased.
Our top 5 customers accounted for 58% of the revenue in quarter ended September 30, 2026, and 56% during quarter ended September 30, 2025, respectively.
The following table has the breakdown of our revenues for the quarter ended September 30, 2026, and 2025 for each of our top 5 customers.
Top Five Customers Revenue for quarter ended September 30, 2026, and 2025.
(In thousands, except percentages)
| Quarter ended September 30, 2026 | Quarter ended September 30, 2025 | |||||||||||||||
| Customer | Amount | % of Revenue | Amount | % of Revenue | ||||||||||||
| Customer 1 | $ | 2,647 | 29 | % | $ | 689 | 20 | % | ||||||||
| Customer 2 | 745 | 8 | % | 583 | 17 | % | ||||||||||
| Customer 3 | 688 | 8 | % | 296 | 8 | % | ||||||||||
| Customer 4 | 663 | 7 | % | 235 | 7 | % | ||||||||||
| Customer 5 | $ | 588 | 6 | % | $ | 133 | 4 | % | ||||||||
| (*) | acquired as part of business combination during the period ended September 30, 2026. |
The following table provides details of Customer 1 revenue by operating segments:
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Software services | $ | - | $ | - | $ | - | - | % | ||||||||
| Customer engagement services | 2,647 | - | 2,647 | 100 | % | |||||||||||
| Managed services and support | - | 689 | (689 | ) | (100 | )% | ||||||||||
| Total Revenue | $ | 2,647 | $ | 689 | $ | 1,958 | 284 | % | ||||||||
Total revenue from Customer 1 increased by $1.96 million, or 284%, to $2.65 million for the quarter ended September 30, 2026, as compared to $0.69 million for the quarter ended September 30, 2025. Customer 1 did not generate Software Services revenue in either the quarter ended September 30, 2026, or the quarter ended September 30, 2025. Customer engagement services revenue increased by $2.65 million, or 100%, to $2.65 million for the quarter ended September 30, 2026, as compared to nil for the quarter ended September 30, 2025. Managed Services and Support revenue decreased by $0.69 million, or 100%, to nil for the quarter ended September 30, 2026, as compared to $0.69 million for the quarter ended September 30, 2025.
Cost of Revenue (exclusive of depreciation/amortization)
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Cost of revenue (exclusive of depreciation/amortization) | $ | 7,035 | $ | 2,871 | $ | 4,164 | 145 | % | ||||||||
Cost of revenue, excluding depreciation and amortization, increased by $4.16 million, or 145%, to $7.04 million for the quarter ended September 30, 2026, as compared to $2.87 million for the quarter ended September 30, 2025.
39
Research and Development
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Research and development | $ | 231 | $ | 59 | $ | 172 | 292 | % | ||||||||
Research and Development expenses increased by $0.17 million, or 292%, to $0.23 million for the quarter ended September 30, 2026, as compared to $0.06 million for the quarter ended September 30, 2025.
Sales and Marketing
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Sales and marketing | $ | 1,538 | $ | 1,022 | $ | 516 | 50 | % | ||||||||
Sales and Marketing expenses increased by $0.52 million, or 50%, to $1.54 million for the quarter ended September 30, 2026, as compared to $1.02 million for the quarter ended September 30, 2025.
Sales and Marketing expenses for the quarters ended September 30, 2026, and 2025, were $1,538 and $1,022, of which advertisement expenses were $891 and $649 respectively.
General and Administrative
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| General and administrative | $ | 2,213 | $ | 2,085 | $ | 128 | 6 | % | ||||||||
General and Administrative expenses increased by $0.13 million, or 6%, to $2.21 million for the quarter ended September 30, 2026, as compared to $2.09 million for the quarter ended September 30, 2025.
Depreciation and Amortization
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Depreciation and amortization | $ | 74 | $ | 63 | $ | 11 | 17 | % | ||||||||
Depreciation and Amortization expenses increased by $0.01 million, or 17%, to $0.07 million for the quarter ended September 30, 2026, as compared to $0.06 million for the quarter ended September 30, 2025.
40
Interest Expense
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Interest expense | $ | 80 | $ | 32 | $ | 48 | 150 | % | ||||||||
Interest expenses increased by $0.05 million, or 150%, to $0.08 million for the quarter ended September 30, 2026, as compared to $0.03 million for the quarter ended September 30, 2025.
Other income
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Other income | $ | 190 | $ | 731 | $ | (541 | ) | (74 | )% | |||||||
Other income decreased by $0.54 million, or 74%, to $0.19 million for the quarter ended September 30, 2026, as compared to $0.73 million for the quarter ended September 30, 2025.
Changes in fair value
| Quarter ended | ||||||||||||||||
| September 30, | ||||||||||||||||
| (In thousands) | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Changes in fair value | $ | 629 | $ | - | $ | 629 | 100 | % | ||||||||
Changes in fair value increased by $0.63 million, or 100%, to $0.63 million for the quarter ended September 30, 2026, as compared to nil for the quarter ended September 30, 2025.
Forex loss
| Quarter ended | ||||||||||||||||
| September 30, | ||||||||||||||||
| (In thousands) | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Forex loss | $ | 26 | $ | 14 | $ | 12 | 86 | % | ||||||||
Forex loss increased by $0.01 million, or 86%, to $0.03 million for the quarter ended September 30, 2026, as compared to $0.01 million for the quarter ended September 30, 2025.
Nine Months Ended September 30, 2026, Compared to Nine Months Ended September 30, 2025
Revenue increased by $17.41 million, or 162%, to $28.16 million for the nine months ended September 30, 2026, as compared to $10.75 million for the nine months ended September 30, 2025, primarily due to $19.71 million of revenue from the Customer Engagement Services segment acquired effective January 1, 2026. Revenue from Software Services decreased by $2.00 million, or 32%, to $4.30 million, and revenue from Managed Services and Support decreased by $0.30 million, or 7%, to $3.94 million, while revenue from All others remained unchanged at $0.21 million.
Cost of revenue, excluding depreciation and amortization, increased by $12.31 million, or 132%, to $21.62 million for the nine months ended September 30, 2026, as compared to $9.31 million for the nine months ended September 30, 2025, primarily due to $14.22 million of cost of revenue of the Customer Engagement Services segment. Gross margin increased to 23.2% for the nine months ended September 30, 2026, from 13.4% for the nine months ended September 30, 2025.
41
Sales and marketing expenses increased by $2.03 million, or 101%, to $4.04 million; general and administrative expenses increased by $5.79 million, or 130%, to $10.25 million; and research and development expenses increased by $0.11 million, or 43%, to $0.37 million, in each case for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025, primarily reflecting the inclusion of the acquired Teyame and Datono operations and transaction, integration and professional costs. Depreciation and amortization increased by $1.34 million to $1.41 million, primarily due to amortization of intellectual property and depreciation of furniture and equipment.
Changes in fair value of $3.72 million for the nine months ended September 30, 2026 (nil for the nine months ended September 30, 2025) relate to the 2025 Convertible Notes and 2026 Convertible Notes, which are measured at fair value (see note 10). Interest expense decreased by $0.21 million, or 46%, to $0.25 million, and other income decreased by $0.22 million, or 26%, to $0.64 million. As a result, net loss increased to $13.15 million for the nine months ended September 30, 2026, from $4.97 million for the nine months ended September 30, 2025.
Revenue, Cost of Revenue and Operating Profit by Operating Segments
During the three months ended September 30, 2026, the Company refined and simplified the presentation of its segment disclosures in accordance with ASC 280, Segment Reporting, to better align with the financial information regularly provided to its Chief Operating Decision Makers (“CODMs”) for evaluating operating performance and allocating resources.
We manage and report our business under four operating segments which are Software Services, Managed Services and Support, Customer Engagement Services, and All others.
The revised presentation focuses on reportable segment revenues, the measure of segment profit or loss used by the CODMs and other disclosures required under ASC 280. Amounts previously presented under “Corporate and Others” have been reclassified, as applicable, to “All others” non-reportable business activities or unallocated corporate reconciling items, as corporate activities do not constitute a reportable operating segment.
Comparative segment information for the three and nine months ended September 30, 2025 has been reclassified to conform to the current-period presentation. These changes have no impact on the Company’s previously reported consolidated financial position, results of operations or cash flows.
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Software services | $ | 1,202 | $ | 2,040 | $ | (838 | ) | (41 | )% | |||||||
| Managed services and support | 1,316 | 1,379 | (63 | ) | (5 | )% | ||||||||||
| Customer engagement services(*) | 6,525 | - | 6,525 | 100 | % | |||||||||||
| All others | 73 | 70 | 3 | 4 | % | |||||||||||
| Revenue | $ | 9,116 | $ | 3,489 | $ | 5,627 | 161 | % | ||||||||
42
Revenue from Software services decreased by $0.84 million, or 41% to $1.20 million for the quarter ended September 30, 2026, as compared to $2.04 million for the quarter ended September 30, 2025. Revenue from Managed services and support decreased by $0.06 million, or 5% to $1.32 million for the quarter ended September 30, 2026, as compared to $1.38 million for the quarter ended September 30, 2025. Revenue from Customer engagement services increased by 100% to $6.53 million for the quarter ended September 30, 2026, as compared to nil for the quarter ended September 30, 2025. Revenue from all others increased by 4% to $0.07 million for the quarter ended September 30, 2026, as compared to $0.07 million for the quarter ended September 30, 2025.
Factors affecting revenues of Software Services, and Managed Services and Support
Our strategy is to achieve meaningful long-term revenue growth through sales of Managed Services and Support to existing and new clients within our target market. In order to increase our cross-selling opportunity between our operating segments and realize long time revenue growth, our focus has shifted more towards Managed Services and Support which is of recurring nature when compared to Software Services segment which is of non-recurring nature. This also helps in retaining existing customers by leveraging our Managed Services and Support and Platform Services as a growth agent. This renewed focus on driving demand for subscription and platform-based model will help us in expanding our customer base and enhance customer retention which is a challenge for our existing Software Services segment. Software Services contracts are driven by Time and Material and on-site employees delivering services at customers location.
Cost of Revenue
| Quarter ended September 30, | Changes | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Software services | $ | 1,041 | $ | 1,738 | $ | (697 | ) | (40 | )% | |||||||
| Managed services and support | 1,009 | 1,092 | (83 | ) | (8 | )% | ||||||||||
| Customer engagement services | 4,706 | - | 4,706 | 100 | % | |||||||||||
| All others | 279 | 41 | 238 | 580 | % | |||||||||||
| Cost of revenue | $ | 7,035 | $ | 2,871 | $ | 4,164 | 145 | % | ||||||||
Cost of revenue for Software services decreased by $0.70 million, or 40%, to $1.04 million for the quarter ended September 30, 2026, as compared to $1.74 million for the quarter ended September 30, 2025. Cost of revenue for Managed Services and Support decreased by $0.08 million, or 8%, to $1.01 million for the quarter ended September 30, 2026, as compared to $1.09 million for the quarter ended September 30, 2025. Cost of revenue for Customer engagement services increased by $4.71 million, or 100% for the quarter ended September 30, 2026, as compared to nil for the quarter ended September 30, 2025. Cost of revenue for all others increased by $0.24 million, or 580%, to $0.28 million for the quarter ended September 30, 2026, as compared to $0.04 million for the quarter ended September 30, 2025.
Segment operating results by reportable segments were as follows:
Operating results by Operating Segment
| Three months ended September 30, 2026 | ||||||||||||||||||||||||||||
| Software Services | Managed Services | Customer Engagement Services* | All others | Total Reportable Segments | Corporate and other items | Consolidated Total | ||||||||||||||||||||||
| Revenue | $ | 1,202 | 1,316 | 6,525 | 73 | 9,116 | - | 9,116 | ||||||||||||||||||||
| Cost of revenue | (1,041 | ) | (1,009 | ) | (4,706 | ) | (279 | ) | (7,035 | ) | - | (7,035 | ) | |||||||||||||||
| Sales and marketing | (117 | ) | (114 | ) | (444 | ) | - | (675 | ) | (863 | ) | (1,538 | ) | |||||||||||||||
| General and administrative | (186 | ) | (46 | ) | (1,259 | ) | - | (1,491 | ) | (722 | ) | (2,213 | ) | |||||||||||||||
| Others, net | (45 | ) | - | 30 | - | (15 | ) | (861 | ) | (876 | ) | |||||||||||||||||
| Profit / (Loss) before income taxes | $ | (187 | ) | 147 | 146 | (206 | ) | (100 | ) | (2,446 | ) | (2,546 | ) | |||||||||||||||
| (*) | represents segment acquired as part of business combination. See note 6(B) for details. |
43
| Three months ended September 30, 20251 | ||||||||||||||||||||||||
| Software Services | Managed Services | Others | Total Reportable Segments | Corporate and other items | Consolidated Total | |||||||||||||||||||
| Revenue | $ | 2,040 | 1,379 | 70 | 3,489 | - | 3,489 | |||||||||||||||||
| Cost of revenue | (1,738 | ) | (1,092 | ) | (41 | ) | (2,871 | ) | - | (2,871 | ) | |||||||||||||
| Sales and marketing | (280 | ) | (173 | ) | - | (453 | ) | (569 | ) | (1,022 | ) | |||||||||||||
| General and administrative | (652 | ) | (299 | ) | - | (951 | ) | (1,134 | ) | (2,085 | ) | |||||||||||||
| Others, net | - | - | - | - | 583 | 583 | ||||||||||||||||||
| Profit / (Loss) before income taxes | $ | (630 | ) | (185 | ) | 29 | (786 | ) | (1,120 | ) | (1,906 | ) | ||||||||||||
| (1) | Comparatives have been rearranged for the purposes of comparison. |
Due from related parties:
On January 1, 2025, the Company entered into a Master Service Agreement with SecureKloud Technologies Inc. (“SKI”) and SecureKloud Technologies Limited (“SKL”). The initial term of the agreement is twenty-four months, which is extendable based on mutual consent. As per the Master Services Agreement, SKI and SKL provide technical resources according to the statement of work from the Company. Pricing is determined using a cost-plus model, with a markup of 18% on cost, to ensure that the transactions comply with the arm’s length principle in accordance with the applicable transfer pricing regulations.
As of September 30, 2026, and December 31, 2025, the balances outstanding are $1,975, and $3,826 respectively. The balances are unsecured, non-interest bearing and are expected to be settled in the ordinary course of business, as outlined below:
| - | $3,200 was advanced to SecureKloud Technologies Ltd. in connection with the design, develop and deliver an Integrated Health Advisory & Care Platform & Tools including certain artificial intelligence-enabled software tools and related intellectual property, intended to support the Company’s current and future product offerings, During the period ended September 30, 2026, progress billings amounting to $1,225 were moved to platform work-in-progress (See note 9), and accordingly, $1,975 remained as advance as of September 30, 2026. |
44
On June 24, 2026, the Company entered into a Securities Exchange Agreement with SecureKloud pursuant to which certain preferred equity securities held by SecureKloud were exchanged for shares of the Company’s common stock on July 28, 2026, following receipt of stockholder approval. In connection with the July 28, 2026, exchange and extinguishment of the Series B Convertible Preferred Stock, the Company assessed the qualitative nature and integrated terms of its settlement with SecureKloud, a related party, and concluded that settlement of the $626 advance represented consideration transferred in the equity exchange rather than a separate settlement expense. Accordingly, the Company reversed the $626 provision during the period ended September 30, 2026, and included the advance settlement in the consideration accounted for directly within stockholders’ equity. The adjustment reduced third-quarter expense and the deemed contribution arising from the preferred-stock extinguishment by $626 each. The combined adjustment was noncash and had no effect on total stockholders’ equity at September 30, 2026. Management evaluated the quantitative and qualitative effects, including the nature of the transaction and its effects on earnings and earnings per share, and concluded that the matter was not material to the previously issued interim financial statements for the three and six months ended June 30, 2026, and that recognition of the adjustment in the third quarter did not materially affect the interim financial statements for the three and nine months ended September 30, 2026. See also note 13(B).
| C. | Related party transactions: |
Following are the transactions with related parties during the periods presented:
| Related Parties | Nature of transactions | Quarter ended September 30, 2026 | Quarter ended September 30, 2025 | |||||||
| SecureKloud Technologies Limited, India | Services received and paid for | $ | 1,225 | $ | 470 | |||||
| Amounts advanced | - | 525 | ||||||||
| Healthcare Triangle (Pvt.) Limited, India | Services received and paid for | 530 | - | |||||||
| Amounts advanced | - | - | ||||||||
| SecureKloud Technologies, Inc. | Services received and paid for | - | - | |||||||
| Amounts advanced | - | - | ||||||||
| Services rendered | - | - | ||||||||
| Amounts collected by related party on behalf of the Company | - | 27 | ||||||||
| Rent expenses paid | - | 44 | ||||||||
| Blockedge Technologies, Inc. | Services received and paid for | 60 | 40 | |||||||
| Amounts advanced | - | 140 | ||||||||
| Revenue | - | 9 | ||||||||
| Key management personnel | Remuneration | 309 | 133 | |||||||
| Board of Directors | Compensation | 55 | - | |||||||
| Amount advanced | $ | 40 | - | |||||||
During the period ended September 30, 2026, the Company issued 1,781,745 shares (89,087 shares, subsequent to one-for-twenty reverse stock-split effective October 26, 2026) of common stock to Blockedge Technologies Inc., a subsidiary of SecureKloud Technologies Limited, India, and 1,046,422 shares (52,321 shares, subsequent to one-for-twenty reverse stock-split effective October 26, 2026) to Robinson Vincent, on behalf of SecureKloud Technologies Limited, India, in connection with extinguishment of 1,600,000 Preferred B stock previously held by SecureKloud Technologies Limited, India.
45
Liquidity and Capital Resources
Liquidity
The current ratio measures a company’s ability to pay off its current liabilities (payable within one year) with its total current assets such as cash, accounts receivable, and inventories. The Company’s current ratio, as at September 30, 2026 is 0.62 compared to 1.03 as at December 31, 2025.
The Company’s debt equity ratio, as at September 30, 2026, is 0.25, compared to 1.08 as at December 31, 2025.
The Company does not have inventory and hence the quick ratio is the same as the current ratio.
Sources of Liquidity
| As of September 30, 2026 | As of September 30, 2025 | |||||||
| Cash and cash equivalents | $ | 1,869 | $ | 1,629 | ||||
As of September 30, 2026, our principal sources of liquidity consisted of cash and cash equivalents of $1.87 million. We have financed our operations primarily through financing activities, including sales of our common stock and debt financing. We believe our existing cash and cash equivalents, together with funds available under our At-the-Market Sales Agreement and Equity Line of Credit, will be sufficient to meet our working capital requirements over the next 12 months. Our future capital requirements will depend on many factors including our growth rate, subscription renewal activity, the expansion of sales and marketing activities and the ongoing investments in platform development.
We have incurred recurring losses from operations and negative operating cash flows, and as of September 30, 2026, our current liabilities of $14.38 million exceeded our current assets of $8.86 million. Our 2026 Convertible Notes, with a fair value of $3.60 million as of September 30, 2026, mature on December 12, 2026, and we are generally required to apply 25% of the net proceeds of specified financings toward their repayment. In addition, our ability to sell shares under the Equity Line of Credit and the At-the-Market Sales Agreement is subject to market conditions, trading volume, an effective registration statement and our continued listing on Nasdaq. On October 1, 2026, we received a Staff Delisting Determination from Nasdaq, and we are awaiting the decision of the Nasdaq Hearings Panel. If our common stock were delisted, or if we were otherwise unable to access these facilities on acceptable terms, our liquidity and our ability to fund operations and repay our obligations as they become due could be materially and adversely affected.
Cash Flows
The following table presents a summary of our consolidated cash flows provided by / (used in) operating, investing, and financing activities for the periods indicated:
| Nine months ended September 30, 2026 | Nine months ended September 30, 2025 | |||||||
| Cash flows used in operating activities | $ | (10,207 | ) | $ | (10,156 | ) | ||
| Cash flows used in investing activities | (10,699 | ) | (1,289 | ) | ||||
| Cash flows provided by financing activities | 15,168 | 13,054 | ||||||
| Cumulative translation adjustment | (18 | ) | - | |||||
| Net (decrease) / increase in cash and cash equivalents | $ | (5,756 | ) | $ | 1,609 | |||
Operating Activities
Net cash used in operating activities during the nine months ended September 30, 2026, was $(10.21) million compared to $(10.16) million for the nine months ended September 30, 2025.
46
Investing Activities
Net cash used in investing activities was $(10.70) million for the nine months ended September 30, 2026, compared to $(1.29) million for the nine months ended September 30, 2025.
Financing Activities
Net cash provided by financing activities was $15.17 million for the nine months ended September 30, 2026, compared to $13.05 million for the nine months ended September 30, 2025.
Off-Balance Sheet Arrangements
We do not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes, as of September 30, 2026.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this Item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting
Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) are designed to ensure that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Operating Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), as appropriate, to allow timely decisions regarding required disclosure. We, under the supervision of and with the participation of our management, including our Chief Operating Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Chief Operating Officer and Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective as of September 30, 2026.
Changes in Internal Control over Financial Reporting
There were no changes to our internal control over financial reporting during the quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
47
PART II
OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in routine litigation that arises in the ordinary course of business.
The information concerning legal proceedings involving L1 Capital Global Opportunities Master Fund Ltd. disclosed in Note 15, Legal Matters, and Note 18, Subsequent Events, to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.
Item 1A. Risk Factors.
As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 16, 2026. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Except as previously reported in the Company’s Current Report on Form 8-K filed with the SEC on July 29, 2026 (relating to the issuance on July 28, 2026 of 9,718,373 shares (485,919 shares subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) of common stock in connection with the Teyame acquisition and 2,828,167 shares (141,408 shares subsequent to such reverse stock-split) of common stock pursuant to the Securities Exchange Agreement with SecureKloud, each in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder), during the quarter ended September 30, 2026, the Company did not sell any equity securities that were not registered under the Securities Act.
Issuer Purchases of Equity Securities
On March 11, 2026, the Company announced a share repurchase program authorized by its Board of Directors on March 9, 2026, and effective immediately, permitting the repurchase of up to $2.0 million of its outstanding common stock. The repurchase program does not have an expiration date and may be suspended, modified or discontinued at any time at the Company’s discretion.
During the three months ended September 30, 2026, the Company repurchased an aggregate of 127,248 shares (6,362 shares subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) of common stock in a single transaction under the publicly announced repurchase program.
| Period | Total Number of Shares Purchased(1) | Average Price Paid per Share(1) | Shares Purchased Under Publicly Announced Program | Approximate Dollar Value Remaining Under Program | ||||||||||||
| September 1 - September 30, 2026 | 127,248 | $ | 0.768 | 127,248 | $ | 1.9 million | ||||||||||
| Total | 127,248 | $ | 0.768 | 127,248 | $ | 1.9 million | ||||||||||
The repurchase program permits purchases through open-market transactions, privately negotiated transactions or other permitted means, subject to applicable securities laws and market conditions.
| (1) | Total number of shares and the average price per share represent shares bought prior to the one-for-twenty reverse stock-split effective October 26, 2026. The value subsequent to the reverse stock-split are 6,362 shares and $15.36 per share respectively. |
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable
Item 5. Other Information
During the three months ended September 30, 2026, no director or officer
48
Item 6. Exhibits
| Exhibit No. | Description | |
| 2.1† | Separation and Distribution Agreement, dated as of September 2, 2026, by and between Healthcare Triangle, Inc. and Teyame AI Holdings, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 8, 2026). | |
| 10.1† | Transition Services Agreement, dated as of September 2, 2026, by and between Healthcare Triangle, Inc. and Teyame AI Holdings, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 8, 2026). | |
| 10.2 | First Amendment to the Equity Purchase Agreement, dated September 22, 2026, by and between Healthcare Triangle, Inc. and Hudson Global Ventures, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 25, 2026). | |
| 21.1* | List of subsidiaries of the registrant | |
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2* | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32.1** | Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2** | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| * | Filed herewith. |
| ** | Furnished herewith (Exhibits 32.1 and 32.2 are not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934). |
| † | Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
49
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| HEALTHCARE TRIANGLE, INC. | |
| Date: November 13, 2026 | /s/ Sujatha Ramesh |
| Sujatha Ramesh | |
| Board Director and Chief Operating Officer | |
| (Principal executive officer) | |
| Date: November 13, 2026 | /s/ David Ayanoglou |
| David Ayanoglou | |
| Chief Financial Officer | |
| (Principal financial officer) |
50